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ABSTRACT
Neurotrophic factor glial cell line-derived neurotrophic factor (GDNF), its co-receptor GDNF family 
receptor alpha 1 (GFRa1), and signaling receptor RET tyrosine kinase are essential to enteric 
nervous system (ENS) development; mice knockout for Gdnf, Gfra1 or Ret lack the whole ENS 
distal to the stomach. These Gdnf/Gfra1/Ret knockout mice die at birth because of lack of ENS and 
kidneys hindering analysis of postnatal function of those proteins. Transgenic overexpression 
in animal models on the other hand relates to loss of physiological spatiotemporal regulation 
of gene expression. These two bottlenecks have hindered the understanding of the role and 
therapeutic potential of GDNF/GFRa1/RET signaling in congenital diseases, such as Hirschsprung’s 
disease, and degenerative neurological diseases, such as Parkinson’s disease. To tackle at least 
some of these problems, we have generated and characterized new mouse models with either 
increased or decreased gene expression dose - from the gene’s endogenous locus and limited to 
naturally expressing cells. 
Novel mouse models with increased expression were generated by editing 3’ untranslated region 
(3’UTR) of the Gdnf gene in such a way that the edited 3’UTR lacks binding sites for negative 
regulators such as microRNAs. By preventing the posttranscriptional downregulation via the 
3’UTR we were able to achieve Gdnf overexpression from the endogenous locus limited to the 
naturally Gdnf expressing cells. We showed that 3’UTR replacement or 3’UTR editing results in 
increased GDNF levels in the brain and kidneys, maintaining the spatiotemporal expression 
pattern with positive effects on the dopaminergic system and negative effects on the kidney 
size and urogenital tract development. We also found that 3’UTR regulates GDNF levels in the 
gastrointestinal tract and that 3’UTR controlled GDNF levels determine proportions of neuronal 
subtypes in the ENS. More specifically, inactivation of negative Gdnf 3’UTR regulation enhances 
nitrergic and cholinergic neuron numbers, and leads to increased gastrointestinal transit time, 
increased stool pellet size, and increased stool water content. 
In congenital Hirschsprung’s disease (HSCR) patients, on the other hand, lack of ENS ganglia 
in the distal gut leads to constipation and megacolon. Even though RET mutations are the 
most common cause of Hirschsprung’s disease, no causative mutations in GFRa1 are known. 
However, one study reported low GFRa1 mRNA levels in some HSCR patients, suggesting that 
perhaps instead of being caused by mutations some HSCR cases could be triggered by reduced 
GFRa1 levels. Complicating the establishment of disease etiology in GDNF/GFRa1/RET related 
HSCR, postnatal viable HSCR mouse models with a defect in GDNF/GFRa1/RET signaling are not 
available. Here, we generated GFRa1 hypomorphic mice by insertion of a selectable marker gene 
in opposite transcriptional direction after the Gfra1 exon 6. Insertion of an expression cassette 
in the opposite transcriptional direction often leads to under-expression from the other strand, 
resulting in hypomorph allele. We showed that a 70-80 % reduction in GFRa1 levels in mice 
resulted in congenital Hirschsprung’s disease and associated enterocolitis phenotype with 100 
% penetrance. We were also able to shed light in the chronology of events in the pathogenesis 
of Hirschsprung’s disease associated enterocolitis: first goblet cell dysplasia accompanied by an 
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abnormal mucin phenotype is proceeding into epithelial damage, later followed by microbial 
enterocyte adherence and bacterial tissue invasion which likely leads to death by sepsis. 
Previously all those features had been described in patients but the sequence of events had 
remained unclear.
Our results suggest that dysregulation of GDNF or GFRa1 levels by epigenetic mechanisms may 
play a role in normal and pathogenic development of the enteric nervous system.  
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TIIVISTELMÄ
Gliasolulinjaperäinen hermokasvutekijä (GDNF), sen ligandia sitova reseptori, GDNF perheen 
reseptori alfa 1 (GFRa1), ja signaalin välittävä reseptori RET-tyrosiinikinaasi ovat kaikki 
välttämättömiä ruuansulatuskanavan enteerisen hermoston kehittymiselle. Gdnf-, Gfra1- tai Ret-
poistogeenisilta hiiriltä puuttuu koko enteerinen hermosto mahalaukusta nähden distaalisesti. 
Näiden poistogeenisten hiirten enteeristä hermostoa ei siis pystytä tutkimaan syntymän jälkeen, 
koska poikaset eivät ole elinkykyisiä puuttuvien munuaisten ja enteerisen hermoston takia. 
Lisäksi transgeeniseen yliekspressioon liittyy ongelmia, jotka johtuvat spatiotemporaalisen 
geenin ilmentymisen säätelyn puuttumisesta. Edellä mainitut kaksi eläinmallien yleistä ongelmaa 
ovat haitanneet GDNF/GFRa1/RET viestinvälityksen tutkimista synnynnäisten sairauksien, 
kuten Hirschsprungin taudin, ja hermorappeumasairauksien, kuten Parkinsonin taudin, 
tutkimuksessa. Aiempiin eläinmalleihin liittyvien ongelmien ratkaisemiseksi olemme kehittäneet 
ja karakterisoineet uusia hiirimalleja, jotka joko yli- tai ali-ilmentävät tutkittavaa geeniä 
endogeenisestä lokuksesta, jolloin geenin ilmentyminen rajoittuu sitä luontaisesti tuottaviin 
soluihin.
Geeniä yli-ilmentävät uudet hiirimallit tuotettiin muokkaamalla Gdnf geenin 3′-ei-transloitua 
aluetta (3’UTR) siten, että geenin ilmentymistä vähentävät tekijät, kuten mikroRNA:t, eivät voi enää 
siihen sitoutua.  Kun transkription jälkeistä negatiivista säätelyä estettiin, pystyttiin GDNF:n yli-
ilmentyminen rajoittamaan sitä luontaisesti tuottaviin soluihin. Osoitimme 3’UTR:n korvaamisen 
tai sen muokkaamisen johtavan lisääntyneeseen GDNF-tasoon aivoissa ja munuaisissa siten, että 
spatiotemporaalinen ilmentyminen säilyy vastaavana kuin villin tyypin hiirillä. Suuremmalla GDNF-
tasolla on positiivisia vaikutuksia aivojen dopaminergiseen järjestelmään ja negatiivisia vaikutuksia 
munuaisten ja lisääntymiselinten kehittymiseen.  Lisäksi havaitsimme, että 3’UTR säätelee 
GDNF-tasoa ruuansulatuskanavassa ja vaikuttaa enteerisen hermoston hermosolutyyppien 
suhteisiin. Tarkemmin sanottuna 3’UTR:n kautta tapahtuvan negatiivisen säätelyn estäminen 
lisää etenkin typpioksidia mutta myös asetyylikoliinia välittäjäaineena käyttävän hermotuksen 
määrää ja vaikuttaa luultavasti sitä kautta ruuansulatuskanavan toimintaan hidastaen suolen 
läpikulkuaikaa, suurentaen ulostepellettien kokoa ja lisäten ulosteen vesipitoisuutta. 
Geeniä ali-ilmentävää eläinmallia käytettiin mallintamaan synnynnäistä Hirschsprungin 
tautia. Hirschsprungin tautia sairastavilta potilailta puuttuvat suoliston loppuosan enteerisen 
hermoston gangliot. Tämä aiheuttaa ummetusta ja johtaa paksusuolen laajentumiseen, 
megakooloniin. Vaikka RET-mutaatiot ovat yleisimpiä Hirschsprungin taudin aiheuttajia, 
ei tällaisia tautia aiheuttavia mutaatioita ole löydetty GFRa1-geenistä, vaikkakin yhdessä 
tutkimuksessa on raportoitu Hirscsprungin taudin potilailla vähentyneestä GFRa1-mRNA-tasosta. 
Tämä viittaa siihen, että mutaatioiden sijaan vähentynyt GFRa1:n määrä voi osalla potilaista 
osaltaan vaikuttaa Hirschsprungin taudin patogeneesiin. GDNF/GFRa1/RET-signaloinnin roolin 
tutkimista Hirschsprungin taudissa on vaikeuttanut elinkykyisten eläinmallien puuttuminen. 
Tässä tutkimuksessa kehitettiin GFRa1-hypomorfinen hiirimalli siten, että Gfra1 geenin 6. 
eksonin jälkeen sijoitettiin selektiivinen markkerigeeni vastakkaiseen suuntaan transkriptioon 
nähden. Ekspressiokasetin lisääminen tällä tavalla johtaa usein vähentyneeseen ilmentymiseen 
toisesta juosteesta eli hypomorfiseen alleeliin. Osoitimme, että 70-80 % vähennys GFRa1-tasossa 
aiheuttaa hiirille 100 % penetranssilla fenotyypin, joka vastaa synnynnäistä Hirschsprungin 
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tautia ja siihen liittyvää enterokoliittia. Pystyimme myös selvittämään Hirschsprungin tautiin 
liittyvän enterokoliitin patogeneesin aikajärjestystä: ensin pikarisolujen dysplasia, johon liittyvät 
epänormaalit musiinit, sitten etenevä epiteelivaurio joiden jälkeen mikrobit voivat päästä 
kiinnittymään enterosyytteihin ja etenemään kudokseen, joka taas voi aiheuttaa sepsiksen ja 
kuoleman. Nämä kaikki on kuvattu potilailla, mutta tähän asti järjestys on ollut epäselvä.    
Tulostemme perusteella GDNF tai GFRa1 geenien ilmentymisen epigeneettinen säätely voi liittyä 
sekä enteerisen hermoston normaaliin että tauteihin liittyvään kehittymiseen. 
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Animal models are critical for enhancing understanding on gene function. Animal models with 
modified genes are also instrumental for the development and improvement of therapeutic 
treatments for human diseases (Doyle et al., 2012). While about 10.000 human diseases 
have monogenic origin, the majority of cases are influenced, at least to some degree, by the 
environment. The use of animal models is often required to define genetic contributions and to 
validate cellular and molecular pathways underlying these diseases, (Doyle et al., 2012), which 
allows treatment design strategy development. The number of genes is similar between high and 
low organisms. Instead, the complexity of an organism is in proportion to the non-coding RNA, 
emphasizing the role of spatiotemporal gene expression as well as expression level regulation 
(Levine and Tjian, 2003). While for example knockout animal models have been and still are 
useful in many study settings, there is a growing need for modeling increased or more subtle 
decreases in gene expression.
Neurotrophic factors are small, secreted proteins that support neuronal survival, differentiation, 
function, and maintenance in development and adulthood. Glial cell line-derived neurotrophic 
factor (GDNF), its co-receptor GDNF family receptor alpha-1 (GFRa1), and transmembrane 
signaling receptor tyrosine kinase, RET, are essential to enteric nervous system (ENS) development: 
mice knock-out for Gdnf, Gfra1 or Ret are unviable due to lack of enteric ganglia and kidneys 
(Schuchardt et al., 1994; Moore et al., 1996; Pichel et al., 1996; Sanchez et al., 1996; Enomoto 
Hideki, 1998). GDNF signaling through GFRa1 and RET has pleiotrophic effects on the enteric 
nervous system development, including chemoattraction in directed migration, proliferation, 
survival, and differentiation (Young et al., 1998; Worley et al., 2000; Gianino et al., 2003; Heanue 
and Pachnis, 2007; Uesaka et al., 2008; Uesaka et al., 2013). Previous attempts to study the effects 
of elevated GDNF expression levels in ENS development using random integration of transgenes 
with recombinant promoters or recombinant protein injections have been challenging, with 
problems arising such as wrong expression site or cell type, non-physiological expression levels, 
and wrong developmental timing (Wang et al., 2010; Mwizerwa et al., 2011; Doyle et al., 2012). 
The dearth of studies with postnatally viable conditional knockout animal models and the above 
fundamental technical issues with transgenic overexpression have hindered the understanding 
of the in vivo role of GDNF/GFRa1/RET signaling in ENS development and diseases. Besides the 
crucial role in the ENS development, GDNF is also known for its potent ability to promote survival 
of central nervous system (CNS) midbrain dopaminergic neurons (Lin et al., 1993; Hoffer et al., 
1994), but despite this, newborn GDNF knockout mice as well as adult GDNF conditional knockout 
mice have an intact brain dopaminergic system (Moore et al., 1996; Pichel et al., 1996; Sanchez et 
al., 1996; Kopra et al., 2015).  To further elaborate our understanding of GDNF’s role, both in the 
ENS and in the CNS, we have, as one objective of this thesis, generated and analyzed new mouse 
models with increased GDNF levels from the endogenous locus.
2
Introduction
Gene expression levels are regulated in numerous ways and each step in gene expression is 
not only extremely complex, but also regulated in a well-orchestrated manner. One of the key 
regulatory areas is 3’ untranslated region (3’UTR) which takes part in mostly negative post-
transcriptional regulation of gene expression (Mayr, 2017).  Here, we generated novel mouse 
models with replaced or edited Gdnf 3’UTRs with a reduced number of binding sites for negative 
regulators, such as microRNAs. We showed that Gdnf 3’UTR replacement results in increased 
GDNF expression from the endogenous locus and characterized how 3’UTR mediated gene up-
regulation of GDNF affects the nigrostriatal dopaminergic system (I) and the development and 
function of enteric nervous system (III). In section I, we showed that 3’UTR replacement results in 
increased Gdnf levels in the brain maintaining the striatal spatiotemporal expression pattern with 
positive effects on the dopaminergic system function. In section III, we showed that 3’UTR also 
regulates GDNF levels in the gastrointestinal tract and that the increased GDNF levels resulted in 
hyperganglionosis, changes in proportions of neuronal subtypes favoring nitrergic neurons, and 
changes in gastrointestinal function. 
Hirschsprung’s disease (HSCR) is a congenital malformation where ENS ganglia are missing from 
the distal gut, leading to severe constipation and megacolon (reviewed by (Heuckeroth, 2018)). 
Even though RET mutations are the most common cause of HSCR, no causative mutations in 
GFRa1 are currently known (Butler Tjaden and Trainor, 2013; Goldstein et al., 2013), but in one 
study low GFRa1 levels have been measured in some HSCR patients with semi-quantitative tools 
(Lui et al., 2002). There have been no postnatal viable mouse models of HSCR with a defect 
in GDNF/GFRa1/RET signaling, shifting the focus of HSCR research to HSCR mouse models of 
endothelin-3 signaling pathway, where mouse models are post-natally viable. However, mutations 
in endothelin-3 signaling pathway account for only approximately 5 % of the patient cases (Kenny 
et al., 2010; Bondurand and Southard-Smith, 2016). Because about 50% of HSCR cases stem from 
alterations in RET, viable HSCR mouse models in this signaling pathway would allow comparative 
studies.  To generate GFRa1 hypomorphic mice we utilized insertion of a selectable marker into 
the gene in the opposite transcriptional direction, often resulting in a hypomorphic allele (Meyers 
et al., 1998; Nagy et al., 1998; Wu et al., 2005; Wei et al., 2010; Wang et al., 2011). We showed 
that 70-80 % reduction in GFRa1 levels resulted in a congenital Hirschsprung’s disease and 
associated enterocolitis (HAEC) phenotype with 100 % penetrance in GFRa1 hypomorphic mice. 
With this model system we were able to shed light into chronology of pathogenic events in HAEC, 
showing that goblet cell dysplasia is an early ubiquitous event, followed by increased goblet cell 
proliferation, mucus retention and accumulating epithelial damage providing an environment for 
later bacterial infection.
The mouse models presented in this thesis open further details on how GDNF/GFRa1/RET 
signaling regulates ENS development, composition and adult function and highlight the potential 
of epigenetic mechanisms in controlling GDNF/GFRa1 levels as potential disease drivers in 
congenital ENS disorders.
Review of the literature
3
2. REVIEW OF THE LITERATURE
2.1 MOUSE MODELS
The house mouse (Mus musculus) was the first genetically modified animal model (Jaenisch and 
Mintz, 1974). There are numerous reasons as to why mice have become the most common model 
organism of human diseases: phylogenetic relatedness and physiological similarity to humans, 
ease and cost-effectiviness of maintaining and breeding mice, availability of strains and methods 
to develop new genetically modified animals (reviewed in (Doyle et al., 2012; Gurumurthy and 
Lloyd, 2019)). There is 99 % homology of genes between mice and humans (Waterston et al., 
2002). In the early days, animal research was largely based on spontaneous mutations, like 
spontaneous dominant negative Sox10 mutation in dominant megacolon mice and spontaneus 
gene deletion of Ednrb in piebald lethal mice. These were both used as models of Hirschsprung’s 
disease (Webster, 1974; Hosoda et al., 1994; Southard-Smith et al., 1998). As incidence of 
spontaneous mutations is infrequent, mutations can be induced by random mutagenesis with 
for example radiation or ethylnitrosourea. However, nowadays reverse genetics approaches like 
directed gene recombination are most often used (Doyle et al., 2012).
2.1.1. REVERSE GENETICS METHODS
In gene targeting, modified DNA is introduced to embryonic stem cells and there by homologous 
recombination added to nuclear DNA (reviewed in (Gurumurthy and Lloyd, 2019)). Selectable 
marker genes that give an ability to grow in presence of selective agents normally toxic to cells, 
such as puromycin or neomycin cassettes, giving resistance to these antibiotics, are used to 
separate the transfected mouse embryonic stem (ES) cells. The correctly targeted ES cells are 
injected to blastocysts, thereby incorporating the modified cells into the transgenic animal 
and transferred to pseudopregnant females. Mice resulting from this approach are most often 
chimeras and obtaining germline transmission is needed to establish a founder line. Conditional 
approaches, such as bacteriophage cyclization recombination (Cre) recombinase between pairs 
of loxP sites (Cre/loxP) (Gu et al., 1994) or flippase and flippase recognition target (Flp/FRT) (Lakso 
et al., 1992), can be used for excision/recombination to physically remove selected sequences 
after transformation. Cre and Flp are both members of the λ integrase superfamily of site specific 
recombinases and share a common mechanism of DNA recombination that involves strand 
cleavage, exchange, and ligation (Sadowski, 1995). The conditional allele may be inactivated by 
Cre-mediated recombination, which can be restricted in time or space by crossing to different 
Cre-lines or viral-vector injections encoding for Cre.
However, gene targeting approaches are inefficient and slow compared to genome editing with 
programmable endonucleases, especially Clustered regularly interspaced short palindromic 
repeats and associated Cas proteins (CRISPR-Cas), which is taking over animal model design this 
decade (Cong et al., 2013; Lander, 2016).  Programmable endonucleases can be used for genome 
editing because of their sequence-specific nuclease activity, which enables cleaving DNA at a 
4
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specific site. Why programmable endonucleases, such as Cas9 or Fok1, result in efficient genome 
editing relates to their ability to produce a double-stranded break at any desired location (reviewed 
in (Jasin and Rothstein, 2013)). RNA-guided Cas9 nuclease system has several advantages, such 
as simplicity, price, and efficiency, compared to the ES-cell-based-gene-targeting methods and 
previous non-CRISPR nuclease based platforms (Gurumurthy and Lloyd, 2019). Despite all its 
advantages, the RNA-guided Cas9 nuclease system also poses challenges, such as mosaicism 
(Yen et al., 2014) and off-target effects when applied directly on zygotes (reviewed in (Zhang et 
al., 2015)). 
2.1.2 MOUSE MODELS WITH REDUCED GENE EXPRESSION
One of the most common approaches in genetics has been to disrupt the gene expression by 
knocking out the gene with targeted deletion. A consortium to systematically knockout every gene 
of mouse genome has been set and thousands of different knockout mice have been generated 
and phenotyped ((Hall et al., 2009; Guan et al., 2010) data available in www.kompphenotype.org). 
However, there are several limitation for the knockout approach. First of all, around 15 % of the 
knockout mice are embryonic lethal, preventing the use of knockout approach for many genes 
essential for cell viability (Hall et al., 2009). Second, the interpretation of the phenotype can be 
challenged with complex secondary, tertiary and even further effects resulting as a consequence 
of ablation of a pleiotrophic gene (Doyle et al., 2012). A third limitation is the ability of a living 
organisms to maintain the viability and fitness despite genetic variations, a quality known as 
robustness. Genetic robustness may arise from functionally redundant genetic pathways in 
developmental processes: as reported from several gene modified model organisms, the loss 
of one gene can be compensated by another with similar expression pattern and overlapping 
functions (Tautz, 1992; El-Brolosy and Stainier, 2017). Redundancy in gene families makes absence 
of a phenotype in a knockout model more likely than those for orphan genes (Barbaric et al., 
2007). Robustness may also arise from tightly regulated metabolic, signaling and transcriptional 
networks where loss of a certain gene’s functions may alter the expression of the other genes in 
that particular network (El-Brolosy and Stainier, 2017). 
An improvement to the full knockout approach has been the conditional knockout, where the 
gene is conditionally knocked out only from certain tissues or at certain developmental time point 
restricted in time or space. With conditional ablation, the embryonic lethality may be avoided and 
some of the conditional knockout animals present a phenotype when the full knockout does not 
(El-Brolosy and Stainier, 2017). However, compensation by other genes may still mask effects of 
the studied gene (Barbaric et al., 2007). 
As an alternative to full gene ablation in homozygous knockout animals, heterozygous mutant 
mice with half the gene dose, resulting in reduced function, can provide models with more 
relevance to the genetics of many human disorders, which often do not involve complete loss-
of-function mutations (Kalueff et al., 2007). The embryonic lethality can be most often avoided 
in heterozygous mouse models, but for many genes the 50% reduction in gene activity is 
sufficient to maintain normal or close to normal function. To reduce the gene dose even further, 
a hypomorphic model may be generated with the same methods used for gene targeting (Baker, 
2011). The generation of hypomorphic alleles is not always straight forward. For example, 
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insertion of a selectable marker cassette, such as neomycin or puromycin resistance cassette 
driven by strong promoter, often from cytomegalovirus (CMV) within an intron, may result in 
downregulated expression, a hypomorphic allele, or even in complete inactivation (Meyers et al., 
1998; Nagy et al., 1998; Wolpowitz et al., 2000). A newer approach, such as adding consecutive 
adenosine nucleotides, polyA tracks, to the gene coding sequence in order to decrease translation 
elongation efficiency may also be used to achieve a hypomorphic allele (Arthur et al., 2017). 
While both knockout and hypomorph approaches are useful, many human diseases are instead 
characterized by gene overexpression (Prelich, 2012). Different approaches are needed to study 
these conditions. 
2.1.3 MOUSE MODELS WITH INCREASED GENE EXPRESSION
Transgenic strains of mice are generated by the introduction of exogenous genes or DNA 
sequences (transgenes) that typically integrate as a single chromosomal insertion event.  Random 
integration mutants of constitutive transgene expression in mice are informative, but they often 
do not accurately reflect what occurs in disease states (Doyle et al., 2012). The main problems 
related to transgenic overexpression are: 1) expression levels are too high, even hundreds to 
thousand fold of endogenous expression levels (Vogler et al., 2003; Shi et al., 2012), 2) loss of cell 
type specific expression pattern (Wang et al., 2010), and 3) loss of temporal control in expression 
(Ray et al., 1997; Wang et al., 2010). To combat loss of temporal control, approaches with 
drugs, such as doxycycline or tamoxifen, have been generated to better mimic the endogenous 
expression where the gene is turned on and off when needed. For the loss of cell type specific 
expression, the gene of interest is often expressed under the control of its native promoter but in 
a mutant background (Doyle et al., 2012). However, these improvements are insufficient to mimic 
endogenous expression pattern. 
As the full knock out of a gene in an animal model often results in embryonic lethality or 
compensation confounding interpretation of the phenotype (El-Brolosy and Stainier, 2017) and 
disrupted spatiotemporal expression pattern and high expression levels related to transgenic 
approaches (Doyle et al., 2012), one option to study the effects of genes would be to instead alter 
the gene expression levels from the endogenous locus by addressing gene expression regulation.
2.2 GENE EXPRESSION LEVEL REGULATION 
For eukaryotes, differences in gene expression between cell types are determined by expression 
of different sets of transcription regulators (reviewed in (Lelli et al., 2012). This is needed to form 
complex organisms and to respond to environmental stimuli. By default, eukaryote genes are in 
an “off-state”, needing to be switched on for gene expression. Gene expression level regulation 
is an extremely complex process. Even after the initiation of transcription, each step of gene 
expression can be modulated. Such steps include transcription, RNA processing, RNA transport, 
translation, and post-translational modification. One regulator can often control another 
regulator in a gene regulatory network (for reviews see (Levine and Davidson, 2005; Spitz and 
Duboule, 2008; Lee and Young, 2013)). Trans-regulatory elements are genes, such as transcription 
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factors, that modulate the expression of other genes from a distance through intermolecular 
interactions, hence “acting in trans” (for review see (Lambert et al., 2018)). Cis-acting regulatory 
elements are adjacent to the gene they regulate by interactions between different parts of the 
molecule hence “acting in cis” (For review see (Wittkopp and Kalay, 2011). 
Besides the genetic code imprinted in DNA, epigenetic changes which regulate gene expression 
can also be heritable sometimes, but DNA methylation is influenced also, for instance, by sex 
and life experience (Allis and Jenuwein, 2016; Grimm et al., 2019). In response to environmental 
stimuli, the interplay between epigenetic modifications on DNA and histones is used for 
plasticity in cells that share identical genomes. This is done by providing a means of activating 
or silencing genes to affect gene expression of specific cell types (Smith and Meissner, 2013). 
Epigenetic changes cover epigenetic status of the chromatin, including DNA methylation, histone 
modifications, promoter–enhancer interactions, and noncoding RNA–mediated regulation. DNA 
methylation has been found at practically all regions of the genome, but promoter methylation 
is the best characterized. Promoter DNA methylation, typically occurring within CpG islands, 
results in powerful repression of transcription, primarily by recruiting repressor proteins or 
chromatin modifiers that enhance the binding to histones (Tate and Bird, 1993; Jones et al., 1998). 
CpG islands are short interspersed DNA sequences that deviate significantly from the average 
genomic pattern by being rich in GC and CpG (5’-C-phosphate-G-3’), and predominantly non-
methylated (Deaton and Bird, 2011). In gene promoter regions the methylation of CpG islands is 
associated with loss of gene expression, which is common in development, differentiation, and 
cancer. In a genome wide single-cell dataset of DNA methylation in human embryonic tissue, the 
3’UTR was recently shown to contain the highest DNA methylation levels compared to other non-
coding regions, and this was linked to transcribed genes by correlation analysis (Luo et al., 2018). 
In patients, 3’UTRs have been shown to be subject to epigenetic up-regulation of gene-expression 
through DNA methylation. For example in colorectal cancer methylation in CpG islands of 
3’UTR exons is positively associated with expression of IPF1/PDX1 and OTX1, both of which are 
homeodomain genes with important roles in development and are not expressed in normal 
colon (Smith et al., 2007). Recently many T-Cell activation related genes were also associated with 
upregulation via 3’UTR methylation in several types of human tumor tissue analysis, which could 
be linked to why T cells become “exhausted” and no longer target cancer cells (McGuire et al., 
2019). Methylation in Havcr2 3’UTR resulted in overexpression of the gene in mice. Future studies 
will show how 3’UTR methylation regulates gene expression.
Tissue specific gene expression is driven by both transcription factors and cis-regulatory 
DNA sequences. Mutations affecting the activity of cis-regulatory sequences, instead of the 
transcription factors, are thought to be the most prevalent cause of phenotypic or morphological 
divergence (Wittkopp and Kalay, 2011). This makes non coding sequences, such as 3’UTRs, an 
interesting locus for designing animal models with altered gene expression levels.
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2.2.1 3’ UNTRANSLATED REGION
mRNA has a tripartite structure consisting of a 5’ untranslated region, a coding sequence and a 
3′ untranslated region (3’UTR) (Figure 2.1). Human 3’UTRs are twice as long as other mammals’ 
3’UTRs and about 10 times longer than in worms (Mayr, 2016). This information together with 
occurrence of alternative cleavage and polyadenylation to generate 3’UTR isoforms in more 
than half of the human genes, reflects the complexity of gene expression regulation by 3’UTRs 
(Mayr, 2016, 2017). Interestingly, many genes, especially in the CNS, bear exceptionally long 
3’UTRs (>10 kb), specifically expressed in certain brain areas (Miura et al., 2013). 3’UTRs have cis-
acting evolutionarily conserved sequences important for post-transcriptional gene expression 
regulation (Siepel et al., 2005; Xie et al., 2005). These cis-acting regulatory elements are sequences 
within the untranslated regions, introns or coding regions of precursor RNAs, as well as mRNAs 
which can be selectively recognized by a complementary set of trans-acting factors to regulate 
posttranscriptional gene expression. 3′ UTR cis-elements are usually repeated and often act 
synergistically. Two key groups of conserved cis-acting elements in regulating gene expression 















Figure 2.1. Simplified schema of the posttranscriptional regulation via the 3′UTR. mRNA 
stability and gene expression are regulated by various posttranscriptional modulators interacting 
with the 3′UTR. MicroRNAs (miRNAs) recruit the RNA-induced silencing complex (RISC) to 
specific target regions, leading to mRNA decay mediated by RNases. Instability motifs located 
within the 3′ UTR are targeted by RBPs, resulting in rapid poly(A) tail deadenylation and mRNA 
degradation or stabilization. Single nucleotide polymorphisms (SNPs) in the 3′UTR disrupt the 
nucleotide complementarity needed for miRNA–mRNA interactions, altering the binding capacity 
of miRNAs. SNPs can also change the overall mRNA structure or particular instability motifs 
required for efficient RBP–mRNA interactions. Long non-coding RNAs (lncRNAs) are modifiers of 
miRNA and RBP activity through their sequestration, thereby suppressing their function. Finally, 
shortening of the 3′UTR through usage of alternative polyadenylation sites (pA) affects overall 
mRNA stability by decreasing the number of potential interaction sites/motifs for the previously 
mentioned posttranscriptional modulators. These regulatory elements acting in concert define 
the posttranscriptional regulome of the 3′UTR and ultimately the mRNA turnover and expression 
of a given gene. RBP, RNA binding protein, miRNA microRNA, CDS coding sequence. Modified 
from (Schwerk and Savan, 2015).
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3′ UTRs contain adenylate-uridylate-rich elements (AU-rich elements, ARE) that regulate mRNA 
stability.  ARE, defined as regions containing frequent repeated adenine and uridine base patterns, 
are common in 3’UTRs and intronic regions of mammalian pre-mRNAs and tend to overlap with 
RNA-binding protein binding sites (Bakheet et al., 2018; Otsuka et al., 2019). AU-rich elements 
are particularly common in UTRs of proto-oncogenes, transcription factors and growth factors 
(Caput et al., 1986). RNA binding proteins via ARE binding can then either stabilize mRNA, like 
Hu antigens, or destabilize mRNA, like well-known RNA binding proteins tristetraprolin and AUF1 
(Chen et al., 2001). mRNA degradation directed by ARE can be influenced in trans by exogenous 
factors like cytokines and transcription inhibitors (Kontoyiannis et al., 1999). 
MicroRNAs are a class of single-stranded non-coding RNA molecules with an average 22 
nucleotides that primarily interact with mRNA targets post-transcriptionally to negatively regulate 
expression as a part of epigenetic machinery (reviewed by (Piletič and Kunej, 2016; O’Brien et al., 
2018)). Typically microRNAs are transcribed first to primary microRNAs, are then processed into 
precursor microRNAs and finally to mature microRNAs either through canonical or non-canonical 
pathways (O’Brien et al., 2018). The first discovered microRNA, lin-4, was found to regulate 
temporal development by targeting multiple sites in 3′UTR of lin-14 gene in Caenorhabditis 
elegans (Wightman et al., 1993). However, in mammals any given microRNA alone has only a 
subtle effect on its target and microRNAs rather fine tune the gene expression levels in concert 
(Bartel, 2009). MicroRNA binding sites, MREs, comprise almost half of the conserved motifs in the 
3’UTRs (Xie et al., 2005) and human protein coding genes have maintained their microRNA pairing 
in evolution in more than 60 % of the genes (Friedman et al., 2009). As expected, considering the 
shortness of binding region called “seed-sequence” (usually 6-8 bp), microRNAs are considered 
multivalent, which means that one microRNA can target several hundred genes and regulate 
several proteins in dynamic manner dependent on factors like cell-type or subcellular location, 
abundancy, target mRNA, and microRNA-mRNA interaction affinity (O’Brien et al., 2018). Factors 
predicting higher regulatory power of MREs are, for example, a position in a weaker secondary 
structure (for instance the ends of 3’UTR), complementary 3’ binding of nucleotides 12-17, and 
two MREs close to each other (Grimson et al., 2007).  MicroRNAs interacts most often with 3’UTR 
of target mRNA, reducing protein levels mainly by inducing mRNA degradation and but also 
translational repression (Garneau et al., 2007). However, interaction with 5’UTR, coding sequence 
and promoters is also possible (Lee et al., 2009).  In more rare cases microRNAs can positively-
regulate gene transcription by targeting promoter elements (Majid et al., 2010; Matsui et al., 
2013). Deviant microRNA expression has been linked to a variety of human diseases such as 
cardiovascular diseases (for review see (Wojciechowska et al., 2017)), cancer (for review see (Leva 
et al., 2014)), diabetes (for review see (Guay et al., 2011)) and neurodegenerative disorders (for 
review see (Sharma and Lu, 2018)).
Both the addition and removal of the poly(A) tail are rate-limiting steps of maturation and 
degradation processes that the majority of mammalian mRNAs undergo. Around 70 % of 
human protein coding genes contain at least one alternative poly-adenylation signal in their 
3’UTR sequence which results in alternative 3’UTRs in mRNAs (Derti et al., 2012; Lianoglou et 
al., 2013). The poly(A) tail as such may also have an effect on the fate of the transcript and it 
contains binding sites for poly(A) binding proteins and thus can affect mRNA export, stability and 
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decay (reviewed by (Jalkanen et al., 2014; Tian and Manley, 2017)). Also more than half of the 
mouse genes generate mRNA isoforms with alternative 3’UTRs encoding proteins with identical 
sequences (Hoque et al., 2013; Gruber et al., 2016). Alternative 3′ UTR isoform ratios are tissue and 
cell type specific and change upon activation of signaling pathways during normal development 
and differentiation (Lianoglou et al., 2013; Gruber et al., 2016; Brumbaugh et al., 2018; Freimer 
et al., 2018). The evolution and roles of alternative 3’UTRs are still not well understood and for 
some reason are not intensively investigated. However, alternative 3’UTRs have been suggested 
to affect mRNA localization, mRNA stability and translation efficiency, as well as affecting protein 
functional diversity (Mayr, 2016). Further adding to this complexity, it has been recently suggested 
that the 3’UTR could also mediate protein localization via regions containing ELAVL1 binding sites 
(Berkovits and Mayr, 2015; Gruber et al., 2016). 
One of the key problems of transgenic overexpressing animal models has been the loss of 
spatiotemporal expression pattern after random integration into the genome (Doyle et al., 2012). 
While negative regulation of gene expression through microRNAs is the best established role 
of the 3’UTRs (Oliveto et al., 2017), preventing this inhibition can be hypothesized to result in 
increased mRNA levels. When 3’UTR is genetically modified the gene expression pattern should 
also be retained in the naturally expressing cells, because 3’UTR regulation happens when 
mRNA has already been transcribed and when other parts of the gene regulatory orchestra have 
already taken care of the spatiotemporal controlling of expression. This makes 3’UTR mediated 
gene expression level regulation such a tempting candidate for increasing gene expression levels 
in the right cells at the right time.  
2.2.1.1 MODELING 3’UTR REGULATION IN MICE
3’UTR regulation of gene expression has previously been studied in a handful of transgenic 
mouse models. The first model of 3’UTR mediated overexpression described was c-fos transgenic 
mice (Ruther et al., 1987). In these animals a high mRNA level could be measured from all tissues, 
when c-fos 3’UTR was replaced with a retroviral long terminal repeat. Thus 3’UTR mediated 
repression was necessary to c-fos level regulation (Ruther et al., 1987). The phenotype resulted 
from deletion of 3’UTR cis elements and overexpression through more efficient mRNA processing. 
In another study, the 3’UTR substitution approach was tested in ES cells and two mouse models. 
The gene modifications in mice resulted in a hypermorph model when At1ar 3’UTR was replaced 
with bovine growth hormone 3’UTR and in a hypomorph model when c-fos ARE was added 
to peroxisome proliferator-activated receptor γ 3’UTR (Kakoki et al., 2004). In a third study, 
transgenic mice carrying a 3′UTR-truncated Hmga2 cDNA overexpressed high mobility group AT-
hook 2 (HMGA2) resulting in proliferative hematopoiesis (Ikeda et al., 2011). Recently, methylation 
of the 3’UTR of an immune checkpoint gene linked to T cell activation in cancer, Havcr2, resulted 
in overexpression of this gene in mice (McGuire et al., 2019). Treating activated T cells with the 
demethylating agent decitabine, or knocking out the DNA methylating enzyme Dnmt3a in mice 
resulted in decreased 3’UTR methylation and gene expression of Havcr2. Therefore, the authors 
suggested that 3’UTR may serve as a functionally relevant site of DNA methylation. 
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3’UTR replacement does not result in increased gene expression and unaffected expression 
pattern of all studied genes. When a 3’UTR with alternative short and long forms is replaced with 
a single poly-(A) signal, normal cellular mRNA localization can be lost. This is seen in the Camk2a 
mouse model (Miller et al., 2002; Mayr, 2018) and Bdnf mouse model (An et al., 2008), with 
both cases leading to impaired memory. Mice with only short Bdnf 3′UTR also become obese, 
a phenotype that could be rescued with an injection of a virus encoding Bdnf with long 3′UTR 
(Liao et al., 2012). This indicates that the long Bdnf 3′UTR plays a role in energy balance (Liao et 
al., 2012).
The results from mice with altered 3’UTRs show that gene expression levels can be decreased 
and increased by 3’UTR replacement or even via methylation of 3’UTR. The data suggests that 
3’UTRs can affect subcellular localization, however, in this situation the expression is still retained 
in the naturally expressing cell types. For GDNF no 3’UTR mediated localization signals have been 
reported. Analysis of RNA sequencing data from neurites versus cell soma of motor-neurons 
has suggested lack of preferential enrichment between these compartments (Rotem et al., 2017; 
Nijssen et al., 2018). Our unpublished data has supported these findings. We cannot however, 
exclude effects in other cell types or under different culturing conditions. 
2.3 NEUROTROPHIC FACTORS AND THEIR 
RECEPTORS
According to the classical neurotrophic factor hypothesis, developing neurons compete for trophic 
support (Hamburger and Levi-Montalcini, 1949). During development, a substantial portion of 
central and peripheral nervous system neurons undergo programmed cell death when lacking 
or not obtaining this support in sufficient amounts (Dekkers et al., 2013). The first characterized 
neurotrophic factor, nerve growth factor, was extracted from mouse sarcoma in the 1950’es by 
the later Nobel Laureates Rita Levi-Montalcini and Stanley Cohen (Levi-Montalcini and Cohen, 
1956; Cohen and Levi-Montalcini, 1957). Based on the ligand structure, neurotrophic factors 
can be divided to three major groups: neurotrophins (reviewed in (Saragovi et al., 2019)), GDNF 
family ligands (reviewed in (Airaksinen and Saarma, 2002; Kim and Kim, 2018)), and neurokines 
(reviewed in (Nathanson, 2012)). However, also an unconventional neurotrophic factor family of 
proteins CDNF and MANF has been described (reviewed in (Lindahl et al., 2017)). Neurotrophic 
factors are small, secreted proteins that support neuronal survival, differentiation, function, 
and maintenance in development and adulthood. Despite the names, neurotrophic factors are 
also important for other cell types and developmental processes. For example, mice lacking the 
potent survival factor for dopaminergic neurons, GDNF, are not viable due to lacking kidneys and 
enteric nervous system, but have an intact dopaminergic innervation at birth (Moore et al., 1996; 
Pichel et al., 1996; Sanchez et al., 1996).  GDNF can be argued to be an interesting candidate for 
studies including altering gene expression levels as GDNF has long and conserved 3’UTR and 
which plays an important role in several developmental processes as well as in neuronal survival.
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2.3.1 GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR 
GDNF signaling together with co-receptor GFRa1 through transmembrane signaling receptor 
RET is an ancient signaling system conserved in vertebrates, including fish, birds and mammals 
(Hearn et al., 1998; Shepherd et al., 2001). The proteins are so similar that zebrafish GDNF and 
GFRa1 can activate human RET and promote survival of mouse dopaminergic neurons in vitro 
(Saarenpaa et al., 2017). Though GDNF family ligands are not found in flies, GFRa and RET have 
orthologues in Drosophila melanogaster (Kallijarvi et al., 2012). Originally GDNF, distant member 
of transforming growth factor beta superfamily, was found from an immortalized glial cell line as 
a factor promoting dopaminergic cell survival in vitro (Lin et al., 1993). GDNF/GFRa1/RET signaling 
is essential in the development of ENS and kidneys, but is also important in the development 
of teeth and eye innervation (Hashino et al., 2001; de Vicente et al., 2002). GDNF also promotes 
the survival or function of many neuronal types, including the midbrain dopaminergic neurons 
and motor neurons (Lin et al., 1993; Henderson et al., 1994; Kopra et al., 2017). Besides GDNF/
GFRa1/RET signaling also has an essential role in spermatogenesis (Naughton et al., 2006) and is 
needed for renewal of many other types of stem cells (Xiao et al., 2014; Peng et al., 2017; Perea 
et al., 2017). 
Classically GDNF family ligands GDNF, neurturin, artemin, and persephin were found to signal 
trough transmembrane signaling receptor tyrosine kinase (RET), encoded by ret proto-oncogene, 
after first binding to corresponding glycosylphosphatidylinositol (GPI) anchored co-receptor GDNF 
family receptor alpha-1 (GFRa1), GFRa2, GFRa3 or GFRa4 (Figure 2.2) (Airaksinen and Saarma, 
2002; Kim and Kim, 2018). As well as GFRa1, GDNF also has weaker affinity for GFRa2 and GFRa3. 
GDNF may also signal through alternative receptors like neural cell adhesion molecule 1 (neurite 
outgrowth or Schwann cell migration (Paratcha et al., 2003; Nielsen et al., 2009)), syndecan 3 
independent of GFRa1 (neurite outgrowth (Bespalov et al., 2011)) and neuropilin 1 (in glioma 
progression (Sun et al., 2017)). Binding of homodimeric GDNF and GFRa1 to RET stimulates 
receptor dimerization (Figure 2.2, (Airaksinen and Saarma, 2002)) and activation of downstream 
signaling pathways, like mitogen-activated protein kinase (MAPK)/ extracellular signal regulated 
kinase (ERK) (Natarajan et al., 2002), phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) 
(Besset et al., 2000), Janus kinase/signal transducer and activator of transcription (Plaza-Menacho 
et al., 2007) or Src family kinases (Popsueva et al., 2003). These signaling pathways are needed 
in processes such as cell differentiation, growth, migration, self-
renewal of embryonic stem cells and survival. 
Figure 2.2. GDND/GFRa1/RET signaling. GDNF activates RET 
tyrosine kinase by first binding to GFRa1-receptor that is attached 
to the plasma membrane by a glycosyl phosphatidylinositol (GPI) 
anchor and is predicted to have three globular cysteine-rich domains. 
(Modified from (Airaksinen and Saarma, 2002)). TK tyrosine kinase.
Although first characterized as neurotrophic factor secreted from 
glial cells in vitro, GDNF has been shown in vivo to be also secreted 
from the developing gut (Hellmich et al., 1996; Natarajan et al., 
2002) and kidney mesenchyme (Durbec et al., 1996; Pichel et al., 
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1996), testicular sertoli cells (Trupp et al., 1995; Hellmich et al., 1996; Meng et al., 2000), and 
striatal parvalbuminergic neurons (Hidalgo-Figueroa et al., 2012). GDNF expression from glial 
cells is evident in vitro from central and enteric nervous system derived glial cells (U87 cells, 
C6 cells, enteric glial cells (Verity et al., 1998; Verity et al., 1999; Le Berre-Scoul et al., 2017)) and 
also in vivo from gliomas (Wiesenhofer et al., 2000).  The abnormal GDNF expression in gliomas 
results from epigenetic modifications in sequence elements unrelated to genetic mutations like 
hypermethylation of GDNF promoter and histone modifications (reviewed in (Ayanlaja et al., 
2018)). Mouse and human GDNF 3’UTRs are conserved and contain several putative binding sites 
for RNA binding proteins (Oh-hashi et al., 2012) and microRNAs (MirTarBase). Whether GDNF 
levels are affected by 3’UTR deletion or replacement has not been studied previously. 
GFRa1 was first discovered using expression cloning to isolate cell surface GDNF-binding proteins 
(Jing et al., 1996; Treanor et al., 1996). It is a cell surface receptor proteolytically processed from 
preprotein to form a mature receptor for GDNF and with lesser affinity to structurally related 
neurturin (Cik et al., 2000). GFRa1 is expressed by several different types of neurons and glial cells 
in both the CNS, PNS, and ENS (Trupp et al., 1997; Yu et al., 1998). Besides the membrane bound 
GPI-anchored form, GFRa1 exists also in a free-floating, soluble form. Activation of GPI-anchored 
GFRa1 induces cis-signaling within the cell to which it is bound, whereas extracellular soluble 
form of GFRa1 may trans-signal upon neighboring cells. GFRa1 may act as an ligand-induced cell 
adhesion molecule where GDNF induces trans-homophilic binding between GFRa1 molecules 
and cell-adhesion between GFRa1 expressing cells in synaptogenesis (Ledda et al., 2007). The 
role of GDNF/GFRa1/RET signaling in ENS development and disease is discussed further in the 
sections 2.5 and 2.6.
2.4 GDNF IN THE CENTRAL NERVOUS SYSTEM
In the CNS, GDNF expression peak is at P15 (Hidalgo-Figueroa et al., 2012). GDNF is expressed in 
numerous brain structures including the striatum, nucleus accumbens, septum, thalamus and 
cerebellum (Trupp et al., 1997; Golden et al., 1998; Hidalgo-Figueroa et al., 2012). In the adult 
murine brain GDNF is expressed by scattered medium sized neurons throughout the striatum 
(Trupp et al., 1997). Of these GDNF expressing neurons, 95 % have been shown to be parvalbumin 
positive (Hidalgo-Figueroa et al., 2012). As well as playing a role in the dopaminergic system 
elaborated in the next chapter, GDNF has also a survival effect on spinal cord motor neurons and 
a role in the axonal growth or guidance and synapse formation of hippocampal neurons, cortical 
neurons, and spinal cord motor neurons in the CNS (Paratcha and Ledda, 2008). 
Besides being a potent neurotrophic factor in vitro for the mesencephalic dopaminergic neurons 
(Lin et al., 1993) GDNF also promotes dopaminergic neuronal survival and neurorestoration of 
adult brains post-injury in rodent and primate animal models (Hoffer et al., 1994; Gash et al., 
1996). This makes GDNF a potential therapeutic candidate for Parkinson’s disease (PD). PD is 
a chronic, progressive neurodegenerative disorder characterized by rigidity, bradykinesia and 
tremor resulting from death of dopaminergic neurons in substantia nigra giving rise to lack of 
dopamine in the striatum (for a recent review see (Del Rey et al., 2018)). GDNF has been studied in 
several clinical trials of PD. As proteins do not penetrate the blood-brain-barrier, GDNF treatment 
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cannot be given orally. Instead the protein needs to be administered directly to the action site 
in the brain. Clinical studies using different administration methods to give GDNF directly to the 
brain have resulted in inconsistent outcomes. Intracerebroventricular delivery of GDNF has failed 
in phase I trials and resulted in a substantial amount of side effects at the same time (Kordower 
et al., 1999; Nutt et al., 2003). The lack of effects with the intracerebroventricular dosing of GDNF 
has been explained by GDNF not reaching the target tissues: the striatum and substantia nigra 
(Kordower et al., 1999; Nutt et al., 2003). In later studies, GDNF was given directly to the striatum. 
Promising results were obtained from Phase I studies where GDNF was administered to the 
striatum (Gill et al., 2003; Slevin et al., 2007) but a randomized phase II study was interrupted 
because of lack of effects (Lang et al., 2006). This was likely as a result of an ineffective pump 
system being unable to distribute GDNF evenly (Salvatore et al., 2006; Morrison et al., 2007). 
The newest clinical trials treating PD with GDNF give some hope for restoring the dopaminergic 
phenotype of some cell bodies when given as an infusion to the putamen in every 4 weeks but 
motor improvements were seen only in the open label study (Whone et al., 2019a; Whone et al., 
2019b).
Interestingly, mice knockout for GDNF, GFRa1 or RET have intact dopaminergic system at birth 
(Schuchardt et al., 1994; Moore et al., 1996; Pichel et al., 1996; Sanchez et al., 1996; Enomoto Hideki, 
1998) but, as mentioned previously, these mice are unviable because of congenital defects in the 
kidneys and ENS. This makes it impossible to study postnatal maturation of the dopaminergic 
system. In 2008, it was suggested by Pascual et al. that GDNF is required to maintain the adult 
dopaminergic system (Pascual et al., 2008). In the study by Pascual et al. one Gdnf allele was 
knocked out and the other was “floxed”. Esr1-Cre was then used for the adult full knockout of 
Gdnf via a high dose of tamoxifen at 2 months of age. The mice presented a PD phenotype seven 
months later, with hypokinesia and decreased dopamine synthesis rate limiting enzyme tyrosine 
hydroxylase (TH). However, these results were challenged by a later study, where GDNF did not 
affect the number or survival of catecholaminergic neurons in three different Gdnf conditional 
knockout mouse models (Kopra et al., 2015). First, Gdnf deletion with Nestin Cre from the CNS 
around embryonic day 10 did not have an effect on the dopaminergic system. The lack of effects in 
the Nestin Cre conditional Gdnf knockout could possibly be explained by compensation by other 
trophic factors, a phenomenon often associated with developmental models. In second and third 
approach, Gdnf was deleted from adult animals either locally, using intrastriatal unilateral AAV Cre 
delivery, or by repeating the experimental protocol published in the study by Pascual et al. 2008. 
The authors reported spontaneous deletion of Gdnf between 2-5 months of age independent of 
tamoxifen application in Esr1-Cre mouse line. This showed that Esr1-Cre induces recombination 
also without the presence of tamoxifen. There was no effect in the number, survival or function 
of the catecholaminergic neurons in the two adult knockout models nor in the developmental 
deletion model. The three complementary approaches showed that GDNF reduction or deletion 
did not lead to any significant changes in the number of central monoaminergic neurons. 
However, rather than controlling dopamine neuron numbers, endogenous GDNF in the striatum 
regulates the function of dopamine neurons. In a later study with adult onset striatal AAV-Cre 
delivery Gdnf conditional knockout mice were shown to display reduced spontaneous and 
amphetamine induced locomotor activity and striatal dopamine efflux (Kopra et al., 2017). In the 
same study embryonic Gdnf deletion with Nestin Cre did not affect striatal dopamine levels or 
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dopamine release, but dopamine reuptake was increased due to increased levels of both total 
and synaptic membrane-associated dopamine transporters (DAT) (Kopra et al., 2017). Hence, 
Gdnf deletion seems to have an effect on the dopamine system function in these mouse models. 
Activation of endogenous GDNF production therefore still has interesting therapeutic potential 
for Parkinson’s disease and should be further explored.
2.5 ENTERIC NERVOUS SYSTEM
At the end of the 19th century, Englishmen William M. Bayliss and Ernest H. Starling performed 
a historical experiment in dogs, where they induced pressure to intestinal lumen resulting in 
oral contraction and anal relaxation allowing production of a propulsive wave: nowadays called 
peristaltic reflex (Bayliss and Starling, 1899). This reflex persisted even after extrinsic nerves were 
severed and the enteric nervous system (ENS) was specified as a self-contained hub independent 
of CNS input. This was confirmed year 1917 in vitro, as peristaltic reflex remains in isolated gut 
(Trendelenburg, 2006). Besides peristalsis, ENS regulates secretions, blood supply and immune 
responses in the gastrointestinal (GI) tract. 
Due to its structural complexity and ability to remain functional without the CNS, ENS is often called 
“the brain in the gut” or “the second brain”.  Many features of the ENS resemble the CNS more 
than other parts of peripheric nervous system: enteric glia resembling astrocytes, no collagen 
in the ganglia, interneurons, microcircuits, a small extracellular space, dense synaptic neuropil, 
isolation from blood vessels, multiple synaptic mechanisms and multiple neurotransmitters 
(Gershon, 1999; Goldstein et al., 2013). Evolutionally the ENS should be considered “the first 
brain”, because this kind of nervous system, consisting of plexuses of intrinsic neurons of the gut 
wall and innervation controlling muscle movements, is found in all animals that have neurons, 
including hydra and echinoderms, which do not possess CNS, that in turn is deduced to be 
bilaterian development (Furness and Stebbing, 2018). Neurochemical similarities across phyla 
imply a common origin of the ENS from hydra to humans (Furness and Stebbing, 2018). Besides 
the ENS, the GI tract is innervated by the CNS controlled extrinsic nervous system consisting of 
sympathetic and parasympathetic pathways. The afferent and efferent network between CNS 
and ENS assures bi-directional message transport between these systems (parasympathetic 
Vagus & pelvic nerves and sympathetic pathways). Interestingly 90 % of vagal afferents between 
ENS and CNS seem to go from the gut to the brain (Furness et al., 2014).  
In mammals the ENS covers the GI tract from the esophagus to the anal sphincter, as a network 
of ganglia distributed to two distinct plexuses: the myenteric plexus in the whole GI tract and the 
submucosal plexus in the intestine. The myenteric plexus is located between the longitudinal 
and circular layers of muscularis externa and is the main neuronal regulator of intestinal motor 
function. The main function of the submucosal plexus located within the connective tissue of the 
submucosa is to control for GI secretion and local blood flow. The ENS projects to the pancreas, 
gallbladder, trachea and prevertebral ganglia. Virtually every class of neurotransmitter found in 
the CNS has also been detected in the ENS (Table 2.1, (Costa et al., 1996; Furness et al., 2014). 
The ENS in the small intestine and colon contains full reflex circuits, including sensory neurons, 
interneurons and several classes of motor neurons, through which gastrointestinal functions like 
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muscle activity, transmucosal fluid fluxes and local blood flow are controlled. Based on marker 
gene expression, morphology, location, and projection targets, approximately ten distinct cell 
types have been described in the myenteric plexus (Furness and Stebbing, 2018; Zeisel et al., 
2018) and four in the submucosal plexus of the mouse (Bornstein, 2008; Furness and Stebbing, 
2018). Based on recent single cell RNA sequencing data, enteric neurons can be roughly split into 
nitrergic and cholinergic groups based on Nos1 and Chat/Slc5a7 expression respectively, where 
calretinin is a marker for some of the cholinergic subpopulations (Zeisel et al., 2018). Considering 
the different tasks of the esophagus, stomach, small and large intestine it is evident that there 
are differences in the ENS of these regions. There are also differences between for example the 
different regions of the colon where the proximal colon has more complex ENS circuits(Li et al., 
2019b). Most of the transcription factors linked to the ENS development have been found to be 
conserved between mouse and humans (Memic et al., 2018). However, in the mature ENS there 
are some differences even between two rodent species, mice and guinea pigs (Gabella and Trigg, 
1984). 
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Table 2.1. Neuronal subtypes of the small intestine ENS (combined from (Bornstein, 2008; 
Furness, 2012)).  MP myenteric plexus, SMP submucosal plexus, EXTR external innervation, 
ChAT choline acetyltransferase, TK tachykinin, IR immunoreactive, ENK enkephalin, NOS nitric 
oxide synthase, VIP vasoactive intestine peptide, 5-HT serotonin, SOM somatostatin, GABA 
γ-aminobutyric acid, PACAP pituitary adenylyl-cyclase-activating peptide, NPY neuropeptide Y
Basic Function Plexus Neurotransmitters and neurochemical markers
Intrinsic sensory neuron, AH/Dogiel 
type II MP ChAT/calbindin/TK-IR
Ascending interneuron MP ChAT/calretinin/TK/ENK
Descending interneuron MP ChAT/5-HT, targets myenteric and/or submucosal ganglia
Descending interneuron MP ChAT/SOM, targets myenteric and/or submucosal ganglia
Descending interneuron MP Ach/ATP/NOS/VIP
Excitatory longitudinal muscle motor 
neuron MP ChAT/calretinin/TK
Excitatory circular-muscle motor neuron MP ChAT/TK, short or long oral projection
Cholinergic secretomotor neuron MP ChAT/NPY/Opioid peptides, CCK, GRP
Intestinofugal neurons to sympathetic 
ganglia MP ChAT/VIP/
Inhibitory longitudinal muscle motor 
neuron MP NOS/VIP/GABA, rare in guinea-pig ileum
Inhibitory circular-muscle motor neuron MP NOS/VIP/PACAP/ENK, short anal projection
Inhibitory circular-muscle motor neuron MP NOS/VIP/PACAP/GRP, long anal projection
Descending interneuron MP NOS/VIP/GRP/±ChAT
Noncholinergic secretomotor neuron MP VIP
Intrinsic sensory neuron, AH/Dogiel 
type II SMP ChAT/TK-IR
Cholinergic secretomotor neuron SMP ChAT/NPY
Noncholinergic secretomotor neuron SMP VIP/PACAP/NPY
Vasodilator neuron SMP ChAT/calretinin, cholinergic
Sympathetic neurons, secretion 
inhibiting EXTR Noradrenaline
Sympathetic neurons, motility inhibiting EXTR Noradrenaline
Sympathetic neurons, vasoconstrictor EXTR Noradrenaline, ATP
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2.5.1 ENTERIC NERVOUS SYSTEM DEVELOPMENT AND 
MAINTENANCE AND GDNF/GFRA1/RET 
The neural crest is a key feature that separates vertebrates from other craniate organisms 
(Gans and Northcutt, 1983). During late gastrulation or early neurulation, the neural crest cell 
population arises at the border between the neural and non-neural ectoderm to delaminate 
from their tissue of origin and migrate to their specific locations (reviewed in (Bronner and 
Simões-Costa, 2016)). In the developing mouse gut, ENS progenitor cells termed enteric neural 
crest-derived cells (ENCCs), from the vagal neural crest somite levels 1-7 enter the foregut on 
embryonic day 9-9.5 (E9-E9.5;  4 weeks of gestation in humans, Figure 2.3) (reviewed in (McKeown 
et al., 2013; Obermayr et al., 2013)). After the relatively small number of precursors enters the 
foregut, ENCCs proliferate actively and in the end generate the millions of enteric neurons and 
glia covering the whole mature intestine (Gianino et al., 2003). ENCCs migrate rostro-caudally 
along the gut towards a GDNF source secreted from the mesenchyme, reach the proximal colon 
at E12, and colon colonization is complete by E14-E14.5 [7 weeks of gestation in humans (Young 
et al., 1998; Sasselli et al., 2012). ENS development is different from PNS and CNS development 
in the sense, that the massive programmed cell death does not occur which likely relates to fetal 
enteric microenvironment being especially rich in trophic support (Chalazonitis et al., 2012). In 
the developing gut GDNF is expressed in the intestinal mesenchyme, while GFRa1 is expressed 
both in the mesenchyme and ENCCs, and RET is expressed only in the ENCCs (Durbec et al., 1996; 
Young et al., 1998; Worley et al., 2000; Young et al., 2001; Lui et al., 2002; Natarajan et al., 2002). 
GDNF, GFRa1, and RET are essential to the enteric nervous system development: a mutation in 
an early-required factor such as GDNF, GFR1 or RET, causes aganglionosis because all lineages of 
neurons in the intestines arise from precursors that require RET stimulation (Schuchardt et al., 
1994; Moore et al., 1996; Pichel et al., 1996; Sanchez et al., 1996; Enomoto Hideki, 1998). 
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Figure 2.3. Mouse ENS development (modified from (Heanue and Pachnis, 2007)). A) The 
precursors for enteric neurons and glia termed enteric neural crest derived cells (ENCC) arising from 
the vagal neural crest enter mouse foregut at embryonic day 9.5 (E9.5).  B) During the migration/
colonization process (approximately E9.5-E14.5) ENCCs are first following a chemoattractant 
GDNF gradient. Behind the wavefront ENCCs proliferate and start to differentiate to neuronal 
and glial lineages. C) By E13.5 the ENCC wavefront has reached approximately the mid colon. 
Besides to the vagal ENCCs, also Schwann cell precursors (SCPs), endoderm derived cells (EDCs), 
and sacral ENCCs contribute to the mature ENS. GDNF, GFRa1 and RET are essential to the ENS 
development affecting migration, proliferation and differentiation. SOX10 SRY box–containing 
gene 10, EDNRB endothelin receptor B, TUJ1 neuron-specific class III beta-tubulin, BFABP brain 
fatty acid binding protein. 
In the hindgut ENCCs can migrate either through a trans-mesenteric pathway (Nishiyama et al., 
2012) or along the caecum to populate the colon (Druckenbrod and Epstein, 2005). In addition, 
truncal and sacral neural crest derived cells contribute to the ENS development (reviewed by 
(Nagy and Goldstein, 2017)). According to Uesaka et al. (Uesaka et al., 2015) there is a 5-20 % 
subpopulation of ENS cells, mostly calretinin positive neurons, in the distal gut, arising from 
Schwann cell precursor lineage during early postnatal development in mice and invading the 
gut through extrinsic innervation. Knocking out Ret specifically from Schwann cell precursors 
resulted in a 30 % loss of ENS cells in the colon of studied mice (Uesaka et al., 2015). Based on 
another recent study on transgenic animals, a small contribution to the small intestine myenteric 
neurons also seems to come from the endoderm derived cells (Brokhman et al., 2019). 
In addition to regulating ENCC migration, GDNF signaling controls the proliferation, differentiation 
and survival of ENCCs (Gianino et al., 2003; Heanue and Pachnis, 2007; Uesaka et al., 2008; 
Mwizerwa et al., 2011; Uesaka et al., 2013). The size of the proliferating pool of precursors is 
critically important for normal ENS development. There is a critical density of cells at the 
wavefront necessary to form the cellular strands that drive ENCC migration (Le Douarin and 
Teillet, 1973, 1974) and a low ENCC density delays the rate of migration (Pomeranz and Gershon, 
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1990; Gershon and Ratcliffe, 2004). Some ENCCs differentiate to neurons during the migration 
process, occurring earliest at E10.5-E11.5 in mice (Rothman and Gershon, 1982; Branchek and 
Gershon, 1989; Young et al., 2002). Neurogenesis continues through development and through 
the first weeks of postnatal period (Pham et al., 1991; Wang et al., 2010; Laranjeira et al., 2011; 
Uesaka et al., 2015). Precursors of different neuronal subtypes exit the cell cycle at different times 
(Pham et al., 1991). The intracellular signaling pathways PI3/AKT and MAPK/ERK were activated 
in avian enteric crest derived cells in vitro by GDNF and PI3/AKT was stimulating proliferation 
(Focke et al., 2001). There seems to be a developmental change as a function of age for GDNF 
from a mitogenic to a differentiation/survival response by the developing enteric neurons 
(Chalazonitis et al., 1998). Premature differentiation of ENCCs has been reported in ovo, which 
has been linked to both reduced and increased GDNF levels (Mwizerwa et al., 2011). The timing of 
this shift corresponded to developmental changes in gut expression of GFRa1, where the GFRa1 
expression has been reported to become increasingly more localized between E13.5 and E19.5 
and to be restricted to myenteric plexus by E19.5 (Worley et al., 2000). The membrane-associated 
GPI-anchored form and the extracellular soluble form of GFRa1 can function cooperatively in 
mediating GDNF signaling in ENCCs (Worley et al., 2000). 
GDNF is needed throughout development and it has been reported to be also abundant in 
the adult gut (Peters et al., 1998), but its postnatal role is not well characterized. Quantitative 
PCR approach has revealed higher levels of RET (20x), GFRa1 (2x), and GFRa2 (2x) mRNA in 
human colonic myenteric ganglia compared to muscle layers, and higher levels of GDNF and 
NRTN expression located to circular and longitudinal muscle layers compared to myenteric 
plexus (Barrenschee et al., 2013). RET, GFRa1 and GFRa2 have also been shown to co-localize in 
myenteric and submucosal ganglia by immunohistochemistry in adult human colon by the same 
authors (Barrenschee et al., 2013). In vitro GDNF can also promote both structural and functional 
plasticity in primary cultures of rat postnatal myenteric neurons (Rodrigues et al., 2011). Here 
the authors suggested enriched neonatal intestinal smooth muscle cells immunoreactive for 
α-smooth muscle actin as a source for GDNF in vitro. Increased GDNF levels have been reported 
in inflammatory bowel disease (von Boyen et al., 2011; Steinkamp et al., 2012). GDNF is proposed 
to be expressed by enteric glial cells (EGCs) in inflammatory states and in vitro (von Boyen et al., 
2011; Steinkamp et al., 2012; Le Berre-Scoul et al., 2017). However, detailed descriptions of GDNF 
expression in the adult gut are missing.
GDNF has been shown to have some therapeutic effects in several rodent models of dextran 
sulfate induced colitis (Zhang et al., 2010; Liu et al., 2014; Meir et al., 2019). In the first mouse 
model of colitis, intracolonic delivery of adenovirus carrying GDNF partly restored intestinal 
epithelial barrier function, which was measured as epithelial permeability and a decrease in 
inflammatory markers (Zhang et al., 2010). The authors suggested that GDNF mediates cross-talk 
between EGCs and mucosal epithelial cells. In the second model, intracolonic adenoviral GDNF 
delivery partly prevented dextran sulfate induced enteric neuron loss, reduced expression of 
some inflammatory markers (tumor necrosis factor and interleukin β) and improved delayed 
colonic transit in rats (Liu et al., 2014). In the third colitis model, recombinant human GDNF partly 
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alleviated inflammation-induced changes in the intestinal epithelial barrier (Meir et al., 2019). 
GDNF levels were also studied in inflammatory bowel disease patients. Decreased GDNF levels 
were measured by ELISA in samples from resected inflamed ileums of Crohn’s disease patients 
and inflamed colons of ulcerative colitis patients (Meir et al., 2019).
Diverticular disease is a widespread disease in industrialized countries initially characterized 
by multiple mucosal or submucosal outpouchings throughout the colon which may lead to a 
broad spectrum of symptoms, typically constipation and flatus. Decreased neuronal density in 
both myenteric and submucosal plexus has been reported in patients with diverticular disease 
(Wedel et al., 2010). Decreased mRNA expression of GDNF, GFRa1 and RET has also been reported 
(Böttner et al., 2013). The authors proposed that hypoganglionosis linked to diverticular disease 
could be due to the lack of neurotrophic support mediated by the GDNF system.
During the latest decade, studies have started to show that the neurogenesis continues in 
postnatal ENS. In a study by Laranjeira et al., locally applied detergent benzalkonium chloride 
was used to dose-dependently ablate the myenteric plexus of a small area of the small intestine 
of adult reporter mice (Laranjeira et al., 2011). They showed that in the damaged mouse gut 
SRY box–containing gene 10 (SOX10) positive neural crest cells generate both neuronal and glial 
lineages of enteric ganglia. Lineage tracing of SOX10 positive precursors showed that 2.8 % of the 
adult undamaged ENS were formed from precursors labeled at P7.5, 1.6 % generated from P30 
progenitors but none from P84 progenitors, indicating that postnatal neurogenesis from SOX10 
positive progenitors is limited after early postnatal stages. Microbiota seems to play an important 
role for the postnatal ENS neurogenesis, since germfree mice display alterations in the ENS, such 
as decrease in nerve density, a decrease in the number of neurons per ganglion and an increase 
in the proportion of myenteric nitrergic neurons(Collins et al., 2014). The changes in the ENS 
of adult germfree mouse gut may be normalized after microbial colonization (De Vadder et al., 
2018). The authors reported maturation of neuronal precursors in the myenteric plexus of the 
colon after microbial transplantation and suggested that the mechanism for this is restoration 
of serotonin signaling through 5-HT4R receptors. The role for serotonin and 5-HT4R receptors 
is supported also by the findings in dextran sulfate sodium induced murine colitis model which 
resulted in increased numbers of myenteric neurons, and this was inhibited by 5-HT4 antagonism 
(Belkind-Gerson et al., 2015). The role of GDNF/GFRa1/RET signaling for postnatal neurogenesis 
has not been studied thoroughly. 
To date the role GDNF/GFRa1/RET signaling in adult ENS function and maintenance is not clear 
and even the expressing cell type is controversial. Further studies are needed to address these 
matters and to dissect the role of GDNF/GFRa1/RET signaling for epithelial barrier function and 
inflammation.
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2.6 ENS RELATED DISEASES AND GDNF/GFRa1/
RET SIGNALING
The importance of the ENS is emphasized by the life-threatening effects of enteric neuropathies. 
A lack of an ENS is life-threatening in most primitive animals that have a nervous system and 
in humans, who cannot survive the congenital lack of an ENS (Furness, 2012). Congenital 
ENS malformations resulting from disruption of NCC development can be classified as 
neurocristopathies, which covers a broad spectrum of congenital malformations. Primary 
developmental disorders of the enteric nervous system can be grouped to ones with abnormal 
number of neurons - aganglionosis, hyperganglionosis, and hypoganglionosis, and ones with 
abnormal differentiation of neurons resulting in changes in biochemical and physiological 
properties like ganglioneuromatosis (Kapur, 2000; Puri and Rolle, 2004). As further defined in 
this thesis, GDNF/GFRa1/RET signaling has a major role in ENS disorders, aganglionosis and 
hyperganglionosis. 
2.6.1 HIRSCHSPRUNG’S DISEASE AND ASSOCIATED 
ENTEROCOLITIS
Congenital megacolon where enteric neurons are missing from the distal part of the gut was 
named after Danish pediatrician Harald Hirschsprung, who reported two cases of “Constipation 
in the newborn as a result of dilation and hypertrophy of the colon” in 1888 (Hirschsprung 1888, 
English translation (1981)). The first descriptions of Hirschsprung’s disease dates earlier to 17th 
century to Dutch physician Fredrick Ruysch (Leenders and Sieber, 1970) and even earlier to 
ancient Hindu surgeons treating the condition with ayurvedic medicine (Raveenthiran, 2011). 
Congenital intestinal aganglionosis is the most common form of congenital ENS malformations 
and affects about one in every 5000 babies, with a 4:1 males to females ratio (Butler Tjaden 
and Trainor, 2013). As a result of the lack of the enteric neurons in distal intestine, typically the 
rectosigmoid colon, the contents of the gut cannot pass normally. This results in functional 
intestinal obstruction, leading to constipation, gut distention (megacolon) and failure to 
thrive. The underlying pathogenic etiology is based on defects in the craniocaudal migration, 
proliferation, differentiation, and survival of ENCCs in the early stage of pregnancy (Amiel et 
al., 2008; Butler Tjaden and Trainor, 2013). HSCR is generally subdivided into short-segment, 
long-segment, and total colonic aganglionosis types based on the point at which histologically 
characterized aganglionosis begins (Ryan et al., 1992). The aganglionated section is surgically 
removed, but somewhat surprisingly, the patients remain at risk of Hirschsprung’s disease 
associated enterocolitis (HAEC) even after the operation (Frykman and Short, 2012).
HSCR is a multigenic disease, with environmental factors affecting the disease prevalence. 
However, the most common genetic cause of HSCR is the presence of inactivating mutations in 
RET. These account for approximately 50% of familial cases and 15-35% sporadic cases (Plaza-
Menacho et al., 2006; Amiel et al., 2008; Kenny et al., 2010; Butler Tjaden and Trainor, 2013). 
In addition to RET mutations, at least 13 other HSCR susceptibility genes have been identified, 
accounting for approximately 20 % of the cases (Plaza-Menacho et al., 2006; Kenny et al., 2010; 
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Ruiz-Ferrer et al., 2011; Butler Tjaden and Trainor, 2013; Goldstein et al., 2013). Even though RET is 
the most common genetic cause for HSCR, mutations in GDNF have been reported only in a couple 
of patients (Ivanchuk et al., 1996; Hofstra et al., 2000; Kenny et al., 2010) and no causative GFRa1 
mutations have been found. However, in one study, reduced levels of GFRa1 in HSCR patients 
have been reported using only semiquantitative tools such as band intensity measurement on 
agarose from semi-quantitative PCR products (Lui et al., 2002). HSCR penetrance is clearly also 
influenced by gene expression levels since copy number variants of MAPK10, ZFHX1B, and SOX2 loci 
were associated with HSCR in a pilot study on 67 candidate genes (Jiang et al., 2011). Currently, in 
approximately half of the sporadic cases of HSCR the underlying genetic cause remains unknown 
(Butler Tjaden and Trainor, 2013; Goldstein et al., 2013).
There is a relationship between 3’UTR RET variants and HSCR (reviewed in (Torroglosa et al., 
2019)). Several RET polymorphisms were characterized in a group of HSCR patients and controls 
(Fitze et al., 2003). Two variants located at the 3’UTR were found (c.3187+47T>C (rs2075912) 
and 30UTR+124A>G)) which had a strong association with HSCR (Fitze et al., 2003). A protective 
RET haplotype has also been identified in the RET 3’UTR: a single nucleotide polymorphism 
g.128496T>C (rs3026785) (Griseri et al., 2007). Here the authors suggested, based on in vitro 
reporter gene expression, that the protective effect of this allele against HSCR might be due 
to lower mRNA degradation. This could lead to an increase of gene transcripts and hence an 
increase in the amount of total RET protein. Seven more haplotypes with negative association 
with HSCR were found in a screening of the RET 3’UTR in a Chinese population (Pan et al., 2012). 
The microRNAs associated with regulation of gene expression by these RET polymorphisms has 
not been elucidated. Epigenetic changes in GDNF and GFRa1 genes have so far not been studied. 
However, by using different tools for bioinformatic analysis (ENSEMBL BioMart for sequences, 
EMBOSS CpGplot for PCpG island prediction) our collaborator  has found a large CpG islands in 
GFRa1 promoter (Saara Ollila, unpublished findings). 
After GDNF/GFRa1/RET signaling, endothelin 3 (EDN3), its receptor endothelin receptor B 
(EDNRB), and its biosynthetic endothelin converting enzyme (ECE1) together are the second most 
common genetic cause for HSCR, being responsible for about 5 % of HSCR cases (Kenny et al., 
2010). However, it has remained controversial as to why EDN3 signaling gives rise to HSCR. Since 
many knockout mouse models of HSCR related genes, including RET, GFRa1 and, GDNF, result 
in total intestinal aganglionosis, HSCR animal research has concentrated on the endothelin-3 
(EDN3) signaling pathway where the knockouts of Edn3, Ednrb, or Ece1 lead to aganglionosis 
of the distal colon (Baynash et al., 1994; Hosoda et al., 1994; Yanagisawa et al., 1998). EDN3 is 
not needed for the formation of enteric neurons, like GDNF/GFRa1/RET signaling, but rather to 
prevent premature differentiation of neuronal precursors and to keep them in proliferative state 
(Hearn et al., 1998; Barlow et al., 2003; Nagy and Goldstein, 2006). EDN3 and GDNF signaling are 
working in a coordinated manner to enhance ENCC proliferation (Barlow et al., 2003). On the 
other hand, EDN3 opposes the GDNF migration and differentiation (Hearn et al., 1998; Barlow et 
al., 2003; Heuckeroth, 2003; Nagy and Goldstein, 2006). There is a need for viable animal models 
with defects in GDNF/GFRa1/RET signaling to counterbalance the bias in HSCR studies towards 
EDN3/EDNRB/ECE. If and why this is important remains to be elucidated once appropriate animal 
models have been generated and fully analyzed. However, it is safe to assume that the best way 
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to mimic human condition is by modulating the causative molecular signaling cascade. As up to 
half of the HSCR cases result from alterations in RET, HSCR mouse models with dampened GDNF/
GFRa1/RET signaling would be relevant for HSCR and related HAEC etiology studies. Next, such 
models would allow comparisons and genetics analysis of endothelin pathway in HSCR/HAEC.
HAEC is the leading cause of mortality in HSCR. It is characterized by altered mucin composition, 
mucin retention, bacterial adhesion to enterocytes, and epithelial damage, although the order 
of these events has been obscure. A recent hypothesis of HAEC pathogenesis includes luminal 
microbial alterations in conjunction with impaired mucosal barrier function and innate immune 
responses, allowing for the bacterial translocation and the development of HAEC (Gosain 
and Brinkman, 2015). However, the pathogenesis of HAEC remains poorly understood. HAEC 
develops in as many as every third patient with short-segment HSCR and every second patient 
with long-segment HSRC (Murphy and Puri, 2005; Frykman and Short, 2012). This suggests either 
multigenic and/or environmental contribution (Frykman and Short, 2012; Demehri et al., 2013). 
Clinical symptoms of HAEC include fever, abdominal distention, diarrhea and sepsis. HAEC is 
histopathologically characterized in the colon by crypt dilatation, mucin retention, enterocyte 
adherence of bacteria, a shift from acidic towards neutral mucin production, epithelial damage, 
leukocyte infiltration, ulceration and, in the terminal stages, transmural necrosis and perforation 
(Murphy and Puri, 2005; Frykman and Short, 2012; Demehri et al., 2013). As mentioned above, 
the sequence of events in HAEC progression is not clear, at least in part because lack of animal 
models genocopying congenital form of HSCR associated to defects in GDNF/GFRa1/RET signaling. 
Mucins are produced primarily by goblet cells and form a protective barrier layer preventing 
bacterial enterocyte adherence (Pelaseyed et al., 2014). The inner colon mucus layer is rapidly 
renewed and converted into the outer mucus layer by controlled endogenous proteolytic 
(Johansson and Hansson, 2013). Decreased levels of the main protein component of these layers, 
the MUC2 mucin have been reported in stool samples from HSCR patients (Mattar et al., 2003). 
Goblet cell hyperplasia (Thiagarajah et al., 2014) and altered goblet cell function (Nakamura et 
al., 2018b) have been reported in HSCR. Altered goblet cell function was proposed to result in 
intestinal barrier dysfunction which would contribute to the development of HAEC (Nakamura et 
al., 2018b). HAEC and inflammatory bowel disease have similar clinical presentations including 
diarrhea, blood in the stools and abdominal pain (Nakamura et al., 2018a). According to a meta-
analysis of HSCR patients, male patients with extensive colonic aganglionosis, who continue to 
suffer from postoperative HAEC post-operatively, are particularly more susceptible to developing 
inflammatory bowel disease (Nakamura et al., 2018a). As GDNF/GFRa1/RET signaling has been 
linked to HSCR and inflammation, further studies are needed to establish whether the defective 
GDNF/GFRa1/RET signaling makes HSCR patients more susceptible to inflammation. 
2.6.1.1 MOUSE MODELS OF HIRSCHSPRUNG’S DISEASE 
Mouse models of Hirschsprung’s disease have been extensively reviewed by Bondurand and 
Southard-Smith (Bondurand and Southard-Smith, 2016). Of the HSCR susceptibility genes, a 
postnatally viable mouse model with colonic aganglionosis, has previously been reported for 
Edn3, Ece, Ednrb, Sox10, Phox2b, and Ttf1. 
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Studies using transgenic mice have shed light on how GDNF signaling regulates the development 
of the enteric nervous system (ENS). As already mentioned, mice that lack expression of genes 
encoding GDNF, GFRa1, or RET have a common phenotype that includes kidney agenesis and a 
lack of enteric ganglia distal to the stomach (Schuchardt et al., 1994; Moore et al., 1996; Pichel 
et al., 1996; Sanchez et al., 1996; Enomoto Hideki, 1998). However, heterozygous Gdnf, Gfra1 or 
Ret null-allele mice with a reduced gene dose, have a relatively mild reduction in enteric neuron 
numbers and do not develop the clinical features of childhood HSCR or HAEC (Gianino et al., 
2003). Only when kept in an isogenic background 20 % of Gdnf knockout heterozygous mice 
develop megacolon because of hypoganglionosis (Shen et al., 2002) but this mouse model does 
not replicate human HSCR with distal aganglionosis (Table 2.2).
The RET gene is alternatively spliced at its 3’ end to produce multiple isoforms, of which RET9 and 
RET51 are the most highly expressed (Tahira et al., 1990). In the intestine, like in most tissues, 
RET9 and RET51 are co-expressed, RET9 being more abundant there (de Graaff et al., 2001; Perea 
et al., 2017). Mice lacking RET9 isomer develop colonic aganglionosis accompanied with small 
and malformed kidneys, while mice lacking RET51 appear healthy (de Graaff et al., 2001). Ret9/-, 
with reduced RET and RET9 expression, have been shown to develop very short segment distal 
colonic aganglionosis with incomplete penetrance and no kidney agenesis (Uesaka et al., 2008). 
However, no postnatal data of megacolon in these mice has been reported. Mouse studies using 
knock-in or timed conditional deletion alleles for Gfra1 or Ret support the importance of GFRa1/
RET signaling in ENS development and survival through postnatal day 1 (P1) (de Graaff et al., 
2001; Uesaka et al., 2007; Uesaka et al., 2008). This means that animal models with defective 
GDNF/GFRa1/RET signaling, that phenocopy postnatal HSCR and/or HAEC, have not previously 
been available. This has led to a bias in the basic research towards the endothelin 3 signaling 
pathway, since these animals are viable after birth (Table 2.2). For further research it is essentially 
important to produce viable HSCR mouse models with defects in GDNF/GFRa1/RET signaling 
because the majority of known HSCR mutations are in RET.
Table 2.2. Selected mouse models of Hirschsprung’s disease for GDNF/GFRa1/RET and 
endothelin 3 signaling pathways (revised from (Bondurand and Southard-Smith, 2016)). ENS 
enteric nervous system, ENCC enteric neural crest derived cell, KO knockout, TIA total intestinal 






















Mouse models Developmental defect Mature phenotype Mouse model references HSCR references 
RET Ret proto-oncogene
Required early factor 














KO mice TIA 
(Schuchardt et al., 1994; de 
Graaff et al., 2001; Gianino 
et al., 2003)
(Attie et al., 1995)
Ret hypomorphic isoforms, humanized 
monomeric isoform, multiple alleles 
that produce only one isoform or 
alter phosphorylation of the receptor 
including Retmi51/mi51, Ret9/-, RetS697A
Decreased ENCCs, failure 
to migrate into fetal 
midgut, compromised 
neuronal survival. 
Depend on mutated 
isoform. 
Colonic aganglionosis
(Schuchardt et al., 1994; de 
Graaff et al., 2001; Uesaka 
et al., 2008)
Rettm3(RET)/mi/+, targeted mutation of 
cytoplasm domain Uncharacterized
Homozygous mice TIA, 
heterozygotes hypoganglionosis 
and reduced fiber density
(Jain et al., 2004)
RettmCti/+ (RetC620R/+) targeted amino acid 
substitution Uncharacterized
Homozygous mice TIA, 
heterozygotes hypoganglionosis 
and reduced fiber density
(Carniti et al., 2006)
Rettm3Cos/tm3Cos (RetS697A/S697A) targeted 
nucleotide substitution
Delayed migration of 
ENCCs into colon
Aganglionosis of mid and distal 









Mesenchyme, in non 
ENCCs
Gdnftm1Lmgd/tm1Lmgd (Gdnf-/-) targeted 
gene knockout




KO mice TIA, hypoganglionosis 
in heterozygotes
(Pichel et al., 1996; Sanchez 
et al., 1996; Gianino et al., 
2003)
(Angrist et al., 1996; 
Ivanchuk et al., 1996; 






GDNF co-receptor for 
RET signaling
Differentiated 
neurons, ENCCs, and 
mesenchyme
Gfra1tmJmi/tmJmi (Gfra1-/-) targeted gene 
knockout
Mediates GDNF signaling 
through RET
KO mice TIA, heterozygotes 
reduced neuron size
(Enomoto Hideki, 1998; 
Gianino et al., 2003) (Lui et al., 2002)
NRTN Neurturin
Size of mature enteric 
neurons and the extent 
of neuronal projections




RET ligand (co-receptor 
GFRa2), promotes neurite 
outgrowth
KO mice have reduced neuron 
size, fiber density, and motility (Heuckeroth et al., 1999)
(Doray et al., 1998; 
Ruiz-Ferrer et al., 
2011)
EDN3 Endothelin 3 Prevent premature differentiation
Mesenchyme, in non 
ENCCs
Edn3ls/ls (Lethal Spotting) Migrations of ENCCs Aganglionosis in distal colon, decreased neuronal numbers (Baynash et al., 1994)
(Hofstra et al., 1996)
Edn3tm1Ywa/tm1Ywa targeted gene 






endothelin 3 ENS precursors
Ednrbs/s (piebald) spontaneous 
insertion in intron, hypomorphic
Defective migration of 
ENCCs into the hindgut
Hypomorphic allele, rare colonic 
aganglionosis
(Hosoda et al., 1994; 
McCallion et al., 2003; 
Yamada et al., 2006)
(Puffenberger et al., 
1994)
Ednrbs-l/s-l (piebald lethal) 
spontaneous gene deletion Uncharacterized
HSCR, decreased AChE fiber 
density in proximal intestine, 
alterations in neuron types in 
ganglionated regions of colon
(Webster, 1973; Fujimoto, 
1988; Hosoda et al., 1994; 
Cantrell et al., 2004)
Ednrbtm1Ywa/tm1Ywa (Ednrb-/-) targeted 
gene knockout Uncharacterized
HSCR, hypoganglionosis of 
proximal intestine
(Hosoda et al., 1994; 









tm1Reh/tm1Reh (Ece1-/-) targeted gene 
knockout
Defective migration of 
ENCCs into the hindgut HSCR (Yanagisawa et al., 1998) (Hofstra et al., 1999)
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2.6.2 INTESTINAL NEURONAL HYPERGANGLIONOSIS
Hyperganglionosis is rarely reported, except for the transition zone between ganglionated and 
aganglionic gut parts in Hirschsprung’s disease (Ure et al., 1994). However, in rare cases chronic 
constipation and/or pseudo-HSCR can be caused by hyperganglionosis. 
Intestinal neuronal dysplasia type B (IND-B) is a condition defined by hyperganglionosis and 
hyperplasia of submucous plexus, but often includes myenteric hyperplasia. IND-B is commonly 
associated with childhood constipation, which sometimes leads to intestinal pseudo-obstruction 
and megacolon with a suggested incidence of 1:7500 (reviewed in (Toledo de Arruda Lourenção 
et al., 2016; Kapur and Reyes-Mugica, 2019)). The symptoms in IND-B patients include nausea, 
vomiting, abdominal distention, abdominal pain, and constipation or even total absence of 
motility. These are similar to symptoms caused by mechanical obstruction in the small intestine, 
such as a tumor or scar tissue. Even life-threatening chronic intestinal pseudo-obstruction has 
been described with associated complications, such as bacterial infections and poor absorption 
of nutrients.  IND-B type of changes are often found in HSCR patients proximal to the transition 
zone (Ure et al., 1994; Kobayashi et al., 1995). There still remains controversy surrounding the 
diagnostic criteria of IND-B. One of the confounding factors in, that the size and distribution of 
the ganglia in control patients varies greatly and has not been thoroughly studied (Coerdt et al., 
2004; Kapur and Reyes-Mugica, 2019). Colonic neuronal hyperplasia was first described by Meier-
Ruge in 1971 in three patients with severe motility disturbances correlating with an increase in 
the number of ganglia both in myenteric and submucosal plexus (Meier-Ruge, 1971). Submucosal 
plexus hyperplasia and giant ganglia that may be 2-3 times the size of normal ganglia are the 
main diagnostic criteria; but inconsistency of these criteria has been in the spotlight when the 
existence of IND-B has been debated (Meier-Ruge et al., 2004; Kapur and Reyes-Mugica, 2019). In 
addition to ganglion size variation in controls, one of the key problems for IND-B diagnosis is the 
fact that submucosal hyperganglionosis may occur in healthy infants (Meier-Ruge et al., 2006). 
IND-B is treated with dietary adjustments, laxatives, and enemas with good results in 80 % of the 
patients (Schimpl et al., 2004). Surgery is an option to patients resistant to conservative treatment 
(Toledo de Arruda Lourenção et al., 2016; Kapur and Reyes-Mugica, 2019). In most of the patients, 
symptoms of IND-B can resolve by the age of 4 years because of the ENS maturation (Bruder 
and Meier-Ruge, 2007). In some patients, degeneration of enteric neurons has been described. 
In a chronic intestinal pseudo-obstruction patient case study, hyperganglionosis was found 
from dilated small intestine segment at the age of 5, but 9 years later the authors described 
hypoganglionosis (Di Nardo et al., 2006). The authors hypothesized that the neuronal hyperplasia 
is related to adaptive changes of the ENS in a response to the obstruction and that also the 
neuronal cell loss, likely by apoptosis, is later triggered by this obstruction. 
Genetic causes of IND-B remain a mystery (Toledo de Arruda Lourenção et al., 2016; Kapur 
and Reyes-Mugica, 2019). Only RET polymorphism has been linked to IND-B (Fernandez et al., 
2009) but as strong a link to IND-B genetics as to HSCR is currently missing. Some different RET 
polymorphisms in isolated IND-B patients, compared to HSCR patients with IND-B or healthy 
controls, have been found (Fernandez et al., 2009). The same study authors also found a R982C 
sequence variant present in three HSCR+IND-B cases and in one isolated IND-B case (Fernandez 
et al., 2009). This, interestingly, has initially been found in a family with both multiple endocrine 
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dysplasia A and HSCR but also with a mutation in codon 618, a typical finding in MEN2A (Mulligan 
et al., 1994). Although the molecular mechanisms associated with the morphological features of 
IND-B are somewhat unclear, knockout mouse models of negative regulators of GDNF/GFRa1/
RET signaling, namely Spry2-/- mice, display enteric neuronal hyperplasia (Taketomi et al., 2005). 
Hyperganglionosis with megacolon is observed in another negative regulator, Kif26a, deficient 
mice (Zhou et al., 2009). These mouse models are further discussed in the next chapter. Three 
main hypothesis have been made for the developmental pathogenesis of IND-B: (i) inhibition 
of normal cell death that occurs in the developing ENS after birth, (ii) excess proliferation of 
the enteric neuronal precursor cells or (iii) a secondary reaction of the ENS to compensate for a 
functional abnormality of the gut (Hatano et al., 1997a). When normal cell death is prevented by 
electroporating a dominant-negative form of caspase-9 into vagal NCCs in the chicken foregut, 
the resulting hyperganglionosis is suggested to be direct result of inhibiting normal cell death in 
ENS precursor cells (Wallace et al., 2009). This supports the first hypothesis. Taken together, both 
the genes and the mechanisms underlying IND-B pathogenesis remain to be discovered. 
Another condition leading to hyperganglionosis is diffuse intestinal ganglioneuromatosis, which 
is an extremely rare disease with benign tumors of ganglionic cells leading to constipation and 
distention of the gut. 40-90 % of diffuse intestinal ganglioneuromatosis is associated with MEN2B 
(Gfroerer et al., 2017). The gastrointestinal symptoms include hypomotility, constipation, diarrhea, 
abnormal sphincter functions, bleeding and diverticula. These can lead to an intestinal pseudo-
obstruction and the development of megacolon (Gfroerer et al., 2017; Castinetti et al., 2018; 
Kapur and Reyes-Mugica, 2019). Pathology findings include submucous and myenteric plexus 
hyperplasia and giant cholinergic ganglia (Feichter et al., 2009; Gfroerer et al., 2017). The severity 
of neural hyperplasia is usually more pronounced than in IND-B and may include grossly obvious 
tumors (Kapur and Reyes-Mugica, 2019). The onset of hyperplasia in ganglioneuromatosis is 
difficult to determine, but it is likely that the lesions keep growing postnatally, even in adulthood 
(Kapur and Reyes-Mugica, 2019). Intestinal ganglioneuromatosis has been reported sometimes 
in conjunction with IND-B (Al-Rikabi et al., 2011). In 95% of MEN2B cases, codon 918 of RET is 
mutated, leading to an exchange of methionine by threonine and leading to constitutive 
activation of RET (Gujral and Mulligan, 2006). Hyperganglionosis has not been reported in MEN2B 
mice (Smith-Hicks et al., 2000), but MEN2A mice, conditionally expressing human RET51 with 
C618F mutation, display enteric hyperganglionosis and C-cell hyperplasia without developing 
thyroid carcinoma (Okamoto et al., 2019). It has been suggested that the genetic alterations 
involved in ganglioneuromatosis could be linked to IND-B by analogy and investigation of these 
pathways including GDNF/GFRa1/RET would improve the understanding of IND-B pathogenesis 
and phenotype (Kapur and Reyes-Mugica, 2019).
2.6.2.1 MOUSE MODELS OF HYPERGANGLIONOSIS
Hyperganglionosis resulting in intestinal obstruction or chronic constipation, is rare, as are the 
mouse models of hyperganglionosis. Altogether eight different postnatal viable mouse models 
with hyperganglionosis have been described (Table 2.3). Two of these can be called intestinal 
neuronal dysplasia B models (Table 2.3, (Hatano et al., 1997a; Zhou et al., 2009)). In one of these, 
GDNF/GFRa1/RET signaling is indirectly affected by inactivation of negative regulators of the RET 
signaling pathway, Kinesin superfamily protein 26A (Kif26A). Another two can be categorized as 
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models of ganglioneuromatosis: mice with targeted MEN2A mutation constitutively activating 
RET and mice with a conditional knockout for Pten (Table 2.3, (Puig et al., 2009; Okamoto et al., 
2019)). Four more miscellaneous hyperganglionic mice have been described, two of which involve 
GDNF/GFRa1/RET signaling (Table 2.3). In addition some embryonic lethal knockout mouse 
models with enteric hyperganglionosis accompanied with other congenital defects have been 
described including Sonic Hedgehog knockout mice (Ramalho-Santos et al., 2000), transcription 
factor Zic2 knockout mice (Zhang and Niswander, 2013), and growth suppressor Gas1 knockout 
mice (Biau et al., 2013; Jin et al., 2015). The postnatal viable mouse models are further described 
in the next chapter. 
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Table 2.3. Postnatal viable mouse models of hyperganglionosis (revised from (Bondurand 
and Southard-Smith, 2016)).
Gene Role in ENS development Animal model Description References
Intestinal neuronal dysplasia mouse models 
Tlx2                              
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2.6.2.2 MOUSE MODELS OF INTESTINAL NEURONAL DYSPLASIA B 
T-cell leukemia homeobox 2 (Tlx2), also known as Ncx/Hox11L.1, is a member of an orphan 
homeobox-containing transcription factor family. It has a role in the development of enteric 
nervous system and it is expressed in several tissues derived from the neural crest (Hatano et al., 
1997a; Hatano et al., 1997b). Hatano et al. (Hatano et al., 1997a) studied targeted knockout of the 
Ncx gene, Ncx−/− mice. All of these mice had hyperganglionic proximal colon and half of these mice 
also develop mega-ileo-ceco-colon and died between 21–35 days of age. Some of these neuronal 
cells degenerated and neuronal cell death occurred in later stages. Yamataka et al. (Yamataka et 
al., 2001) showed that all Ncx−/− mice, with and without megacolon, have abnormal innervation 
in the ileum, cecum and proximal colon. This included hyperganglionosis in both in myenteric 
and submucosal plexus stained with pan-neuronal marker protein gene product 9.5 (PGP9.5) 
immunohistochemistry, ectopic cholinergic ganglia in both neuronal plexuses stained with 
histochemistry, and on nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d) 
histochemistry ghostlike nitrergic ganglia with blurred edges and branching appearance. In 
the distal colon, the ganglions were normally distributed. However, one group was unable to 
reproduce the hyperganglionosis results in Ncx−/−, even though the mice developed a dysmotility 
phenotype (Parisi et al., 2003). The abnormal findings were resembling human intestinal neuronal 
dysplasia B (Toledo de Arruda Lourenção et al., 2016). The megacolon phenotype of Ncx−/− is not 
fully penetrant, and for example, mice in C57BL/6J genetic background are more affected (Parisi 
et al., 2003). Kato et al. (Kato et al., 2009) studied the proximal colon by immunohistochemistry 
of membrane bound neural cell adhesion molecule (NCAM) post-translationally modified with 
poly-sialic acid (PSA). This is a known marker for immature neurons. PSA-NCAM was positive 
in submucosal and myenteric plexuses of the proximal colon in around half of the Ncx−/− mice 
after P14, when WT mice did not show any staining.  It seems that Ncx/Hox11L.1 is required for 
maintenance of proper functions of the enteric nervous system or for differentiation (Hatano et 
al., 1997a; Yamataka et al., 2001; Parisi et al., 2003; Kato et al., 2009). However, the presence of 
mutations or molecular defects in the Hox11L.1 coding region in humans with IND-B have not 
been described (Costa et al., 2000; Fava et al., 2002; Toledo de Arruda Lourenção et al., 2016). 
The kinesin superfamily proteins (KIFs) are motor proteins that transport organelles and 
protein complexes in a microtubule- and ATP-dependent manner. Zhou et al. (Zhou et al., 2009) 
described targeted gene knockout of Kif26a (Kif26a−/−) in mice leading to death between 7-35 
days and megacolon because of GI functional obstruction. Kif26a−/− mice showed myenteric 
hyperganglionosis in the colon, but not in the ileum, with changes being more substantial in the 
distal colon, where about a 50 % increase in both cholinergic and nitrergic neurons was reported. 
ENS precursor proliferation was increased at E12.5 in Kif26a−/− mice. Ganglia were less connected 
by AChE- or NADPH-d-positive fibers in the colon of Kif26a−/− mice and the neurite outgrowth in 
vitro was shorter. Response to cholinergic carbachol stimulus was prolonged in Kif26a−/− mice 
indicating abnormal coordination of colonic motility. In vitro, in a TGW-neuroblastoma cell line, 
overexpression of Kif26a suppressed GDNF/RET mediated ERK and Akt phosphorylation. In 
vitro, RNA interference knock down with targeted microRNA and tissue of primary culture from 
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Kif26a−/− mice showed upregulation of ERK and Akt cascades. Overexpression and knockout 
results suggest that KIF26A inhibits GDNF/RET signaling and downstream activation of ERK and 
Akt cascades, but this has not been shown in vivo. Kif26a−/− mice also exhibit differences in the 
CNS in a form of intense and prolonged nociceptive responses (Wang et al., 2018).
Beside abovementioned mouse models, IND-B type of pathology of giant ganglia in the 
submucosal plexus has been found in two Ednrb knockout heterozygous animal models that 
do not show gastrointestinal dysmotility symptoms (von Boyen et al., 2002; Holland-Cunz et al., 
2003). Homozygous Ednrb deficient rats and mice develop HSCR megacolon but these mice do 
not show IND-B pathology (von Boyen et al., 2002; Holland-Cunz et al., 2003).
Even though in patients IND-B is defined as submucosal hyperganglionosis (Kapur and Reyes-
Mugica, 2019), both the in Ncx−/− and Kif26a−/− mice show hyperplasia present also in the myenteric 
plexus. Despite this, both of these mouse models are considered to model IND-B. There are small 
differences in the ENS development between mice and humans, particularly in the development 
of distal submucosal plexus. In mice, this occurs postnatally and, in humans, early in development 
(Nagy and Goldstein, 2017). As the diagnostic criteria of IND-B are controversial, it is not clear 
from human studies if myenteric ganglia were not measured or they were measured but are not 
different. 
2.6.2.3 MOUSE MODELS OF GANGLIONEUROMATOSIS
Okamoto et al. (Okamoto et al., 2019) studied the RET(C618F) mutation leading to constitutive 
activation of RET, which requires a ligand for full activation and causes multiple endocrine 
neoplasia syndrome (MEN) 2A, leading to medullary thyroid carcinoma and pheochromocytoma. 
Knock-in mouse line conditionally expressed RET(C618F) by Ret promoter. RET(C618F) could be 
knocked out by Cre-loxP recombination to start expressing mCherry.  Mice expressing RET(C618F) 
displayed mild C cell hyperplasia and around a 20 % increase in the total number of PHOX2B 
positive myenteric neurons. The submucosal neurons and specific neuronal subtypes where 
not studied. In MEN2 patients, diffuse intestinal ganglioneuromatosis is solely associated with 
MEN2B mutations (Gfroerer et al., 2017; Castinetti et al., 2018). This is the opposite to these 
findings in mice. Also, the level of ganglionic hyperplasia is much more pronounced in MEN2B 
patients. 
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) regulates cell size and 
proliferation by phosphatazing both proteins and phospholipid substrates. PTEN deficiency may 
alter the MAPK/ERK signaling pathway, and crosstalk to GDNF/GFRa1/RET signaling pathway has 
been shown (Zbuk and Eng, 2006; Salmena et al., 2008). Because Pten knockout is lethal in early 
embryonic development (Stambolic et al., 1998), a conditional Pten knockout approach was used 
to delete PTEN conditionally from ENS precursors, using transgenic Tyr:Cre line (Delmas et al., 
2003; Puig et al., 2009). However, this also affects (or induced Cre recombination in) melanoblasts 
and a subset of smooth muscle precursors. Homozygous conditional Tyr:Cer Pten knockouts died 
between P13-P20 because of intestinal pseudo-obstruction causing constipation, megacecum 
and ileal perforations (Puig et al., 2009). These mice showed increased numbers of both neurons 
and glial cells in myenteric and submucosal plexus. Hyperplasia was occurring after E15.5, when 
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the gut is fully colonized by ENCCs. Besides hyperplasia, Pten cKO mice showed hypertrophy 
of the neurons after birth. The authors showed that absence of PTEN lead to upregulation of 
PI3K/PTEN-AKT-S6K signaling pathway and hyperplasia could be prevented with AKT inhibition by 
antibody treatment. The authors pointed to a link to diffuse ganglionneuromatosis by showing 
low levels of PTEN in 2/7 studied patient samples and high levels of downstream effector of the 
PTEN signaling pathway, S6, by immunohistochemistry.
2.6.2.4 MISCELLANEOUS MOUSE MODELS OF HYPERGANGLIONOSIS
Wang et al. used two transgenic approaches and GDNF injections to elevate GDNF levels in 
mice (Wang et al., 2010). The first transgenic mouse model, Myo-Gdnf  mice, produced excess 
GDNF in developing and mature skeletal muscle (Nguyen et al., 1998). Gdnf overexpression in 
muscles did not lead to an ENS phenotype, except for an increase of nitrergic innervation of the 
esophagus. The expression kinetics for GDNF in the developing intestine were not studied. The, 
second transgenic mouse model, GFAP-Gdnf  mice, produced excess GDNF in central nervous 
system and enteric glia starting around E18 (Zhao et al., 2004). Due to unexplained difficulties 
in breeding and high mortality as newborns of GFAP-Gdnf mice, in a third approach, C57BL/6 
mice were subcutaneously injected with recombinant His-tagged GDNF (2 μg/g s.c.) or phosphate 
buffered saline twice a day for P0-P30. GFAP-Gdnf mice and GDNF injected mice had no increase 
in total number of myenteric neurons. GFAP-Gdnf and GDNF injected mice had small increases 
in small bowel and colon total neuronal and nitrergic myenteric neuron cell size and in total 
submucosal neuron density. There was a 30% increase in small bowel and 47% increase in 
colon NADPH-d neuron density in the myenteric plexus of GFAP-Gdnf mice and a 57% increase 
NADPH-d small bowel myenteric neurons in GDNF injected mice at P30 (Table 2.4). Contraction 
force was increased in both circular and longitudinal muscle of GFAP-Gdnf mice. Also, release of 
vasoactive intestinal peptide and substance P from the small bowel and colon was increased, 
despite the transgene increasing the proportion of NADPH-d positive, but there was no effect on 
ChAT positive neurons (Table 2.4). The ectopic GDNF injections, starting from P1, and transgenic 
Gdnf overexpression, using GFAP promoter starting at E18, resulted in changes in proportions 
of enteric neurons. These results however, tell little about effects of increased endogenous 
GDNF in enteric nervous system development and adult function. Besides mouse models, GDNF 
over expression has been studied with targeted retroviral vector mediated gene transfer in ovo, 
where both decreased and increased GDNF levels caused premature differentiation of enteric 
neurons (Mwizerwa et al., 2011). The development of the avian enteric nervous system has 
more similarities than differences, compared to mammals (Heanue et al., 2016). However, this 
study did not provide data on effects of endogenous GDNF levels on pre,- and postnatal enteric 
nervous system.
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Table 2.4. Key changes in enteric neuronal cell density in GFAP-Gdnf and GDNF injected 
animals summarized from Wang et al. (Wang et al., 2010). Cuprolinic blue staining was used for 
evaluation of total neuronal density. (=) no change compared to controls, NADPH-d nicotinamide 
adenine dinucleotide phosphate diaphorase, ChAT choline acetyltransferase.
GFAP-Gdnf 
small bowel myenteric NADPH-d (+1.3) > ChAT (=)
small bowel submucosal total (+1.19) > myenteric total (=)
colon myenteric NADPH-d (+1.47) > ChAT (=) 
colon submucosal total (+1.7) > myenteric total (=)
GDNF-injected
small bowel myenteric NADPH-d (+1.57)  ChAT not evaluated
small bowel submucosal total (+2,44) > myenteric total (=)
colon myenteric NADPH-d (=)
colon submucosal total (+3,1) > myenteric total (=)
Sprouty and Spred family proteins are evolutionarily conserved inhibitors of tyrosine kinase 
signaling. Taketomi et al. described targeted gene knockout of Sprouty2 in Spry2-/- mice 
that resulted in the death of half of the knockout mice within 6 weeks from birth (Taketomi 
et al., 2005). All the mice showed findings resembling esophageal achalasia at different levels 
accompanied with stronger contraction response to charbachol in lower esophageal sphincter. 
The phenotype was accompanied with hearing loss. Whole-mount immunostaining with an 
antibody against the neuronal marker PGP9.5 demonstrated a marked hyperplasticity in the 
ENS plexus density in the esophagus, ileum and colon. Maximum contraction force in response 
to cholinergic stimulation was reduced. Anti-GDNF IgG antibody treatment and RET-Fc protein 
partly rescued the ENS hyperplasia in Spr2-/- mice. When colonic tissues from WT and KO mice 
were incubated in presence and absence of GDNF (50 ng/ml) in vitro the authors reported a 
prolonged phosporylation of Akt and ERK in knockout gut studies with immunohistochemistry 
and western blotting experiments (Taketomi et al., 2005). In another study, Spr2-/- mice were 
crossed to targeted RetY1062F knock-in mice, where tyrosine 1062 is replaced with phenylalanine 
resulting in variating length of aganglionosis or hypoganglionosis and kidney hypoplasia (Jijiwa et 
al., 2004). This was used to study whether loss of Spry2 would rescue the ENS or kidney phenotype 
(Miyamoto et al., 2011). While the effects of loss of Spry2 for RetY1062F mice were rather small, it 
partially rescued kidney hypoplasia and stomach hypoganglionosis, but did not rescue intestinal 
aganglionosis (Miyamoto et al., 2011). 
Fibroblast growth factor (FGF) family members bind heparin and possess broad mitogenic and 
angiogenic activities. Targeted knockout mice for FGF2 (Fgf2-/-) are viable and do not display 
any obvious neurological deficits (Hagl et al., 2008; Hagl et al., 2013). Whole mount longitudinal 
muscle myenteric plexus preparations stained with pan-neuronal marker PGP9.5 or cupronilic 
blue, showed larger enteric neuron size in ganglia with open architecture of connectives in 
Fgf2-/- mice (Hagl et al., 2008). There was no statistically significant difference in contractility in 
Fgf2-/- mice but chlorine secretion measured in Ussing chamber and mucosal barrier function 
determined with studying bacterial translocation were changed (Hagl et al., 2008). Also, the 
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proportions of the enteric neuronal subclasses are changed in these mice. There is up to a 40 % 
reduction of calbindin-positive neurons in wholemount preparations stained for calbindin and 
calretinin in Fgf2-/- mice (Hagl et al., 2013). The precise role of FGF2 in the ENS development is 
not well established. 
Effects of bone morphogenetic protein (BMP) signaling on ENS development were studied in 
transgenic mice over expressing either the BMP inhibitor, noggin or BMP4 under control of 
the neuron specific enolase promoter causing transgene over expression in neurons and 
enteroendocrine cells (Chalazonitis et al., 2008) . Antagonism of the BMP signaling by noggin 
increased the total numbers of enteric neurons by 40 % and favored the subpopulations 
derived from precursors that exit the cell cycle early in neurogenesis: serotonin, calretinin 
and calbindin. The neuronal subpopulations that exit the cell cycle late were reduced. Those 
included: γ-aminobutyric acid, tyrosine hydroxylase, dopamine transporter, calcitonin gene 
related peptide, and TrkC positive ENS sub-populations. In contrast, overexpression of BMP4 
increased the numbers of TH- and TrkC-expressing neurons. The authors suggested that the 
data supports the idea that the number of proliferative divisions neuronal precursors undergo 
before their terminal mitosis, in part, determines the phenotypic expression in the ENS, and 
that that BMP signaling may regulate enteric neuronal phenotypic diversity by promoting the 
exit of precursors from the cell cycle. Noggin overexpressing mice had only mild GI functional 
deficits, mainly irregular rapid GI transit time, stool size, and water content. The same noggin 
overexpressing mice are more prone to colitis induced with trinitrobenzene sulfonic acid or 
dextran sulfate sodium (Margolis et al., 2011).
In conclusion animal models of hyperganglionosis are relatively rare. However, GDNF/GFRa1/
RET signaling has been linked to most of the existing animal models of hyperganglionosis, 
either directly or indirectly. Generation of novel animal models would help to understand the 
development of hyperganglionosis and shed light into the underlying pathogenesis of this rare 
pathology, which is causing chronic problems to patients who, unlike Hirschsprung’s disease 
patients, often cannot be eased with surgery. It can be speculated that hyperganglionosis may 
also contribute to more common GI problems, such as constipation or irritable bowel syndrome, 
since at least in mice even considerable increase in enteric innervation can have only mild effects 
on GI functions and thus may pass unnoticed. This is even more so in patients, enteric innervation 
is mostly only studied for diagnosis upon severe chronic obstructions. How variable is the size of 
the normal ENS innervation density and if and how this links to common GI tract diseases, such 
as inflammatory bowel disease, is currently unknown. Mouse models of hyperganglionosis may 
help to shed light into this and provide tools for defining and testing treatment.
Aims of the study
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3. AIMS OF THE STUDY
The lack of postnatally viable knockout animal models and fundamental issues with transgenic 
overexpression have hindered the understanding of the role of GDNF/GFRa1/RET signaling in 
the CNS and ENS development and diseases. The aim of this study was to investigate how GDNF 
levels influence the brain dopamine system and how the levels of GDNF, and its receptor GFRa1, 
effect the ENS development and function. 
Specific aims of this study were:
I) to analyze the expression site of Gdnf mRNA and measure DAT and TH levels and MAPK activity 
in GDNF hypermorphic mice striata
II) to characterize the phenotype of GFRa1 hypomorphic mice 
III) to characterize the role of 3’UTR regulation of GDNF expression in enteric nervous system 
development and adult function
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4. MATERIALS AND METHODS
The methods used by the thesis author in publications I-III are listed in Table 4.1. Detailed 
descriptions of materials and methods are provided in the original publications. and according 
supplements. The methods used for additional data included in the thesis are provided in the 
below supplementary materials and methods.
Table 4.1. Methods used by the author 
Method Used in
In situ hybridization, RNAscope I
Corridor test* I
Western blotting I, II
Microdissection I, II, III
Genotyping I, II, III
cDNA synthesis II, III
Quantitative PCR II, III
Tissue processing / sectioning I, II, III
Histochemistry II, III
Immunohistochemistry II, III
Microscopy and quantification I, II, III
GI functional tests III
ELISA* III
HPLC III
BrdU proliferation studies III
Taqman RT-PCR III
*) collaboration / non-inpendent
4.1 SUPPLEMENTARY MATERIALS AND METHODS
Crude synaptosomal preparations and membrane protein biotinylation
The dorsal striata were dissected from adult mouse brain (4 months old, male) and the 
synaptosomal DAT assessment was done as previously described (Kopra et al., 2017). Briefly, the 
mice were sacrificed by decapitation and the dorsal striata were dissected with a scalpel onto ice 
from 2 mm slices cut using a mouse brain matrix (Stoelting). The samples were snap-frozen on 
dry ice and stored at −80°C until assayed. 
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The striata were cut into approximately equal-size pieces and homogenized with a Teflon pestle 
in 0.32 M sucrose. One piece was used to measure total DAT protein levels. Crude synaptosomal 
preparations were prepared as described previously (Hallett et al., 2008). The biotinylated fraction 
of the synaptosome preparation was then extracted using the Cell Surface Protein Isolation Kit 
(Pierce) in accordance with the manufacturer’s instructions.
Western blotting
The dorsal striatum samples were homogenized on ice in 10 mM HEPES (pH 7.2–7.4), 1 mM 
EDTA, 0.3 m sucrose, protease inhibitor mixture (Complete Mini-Tabs Protease Inhibitor; Roche) 
and phosphatase inhibitor (PhosSTOP; Roche). Total protein concentration was measured using 
the Lowry method (Bio-Rad). A total of 10 μg of protein was separated by SDS-PAGE to detect 
DAT. The proteins were transferred to a nylon membrane, which was washed 3 times in TBS 
containing 0.1% Tween 20 (TBS-T) for 15 min and then blocked in 5% (w/v) nonfat milk in TBS-T 
for 1 h at room temperature (RT). To detect DAT, the membranes were incubated in rat anti-
DAT (1:1000, MAB369; Millipore) overnight at 4°C in blocking solution, followed by biotinylated 
anti-rat antibody (1:500, BA-4000; Vector Laboratories) for 2 h at RT, followed by 2 h at RT with 
streptavidin-HRP (1:2500, S-911; Invitrogen).
The membranes were stripped for 15 min at 70°C in 50 mM Tris-HCl, pH 7.4, 2% SDS, and 50 mM 
DTT, and then washed and blocked as described above. The membranes were then incubated in 
mouse anti-GAPDH antibody (1:10,000 or 1:1000 for total and biotinylated samples, respectively; 
MAB374; Millipore) for 2 h at 4°C, followed by 2 h at RT in anti-mouse-HRP (1:3000 or 1:1500 
for total and biotinylated samples, respectively; P0449; DAKO). The signal was visualized using 
enhanced chemiluminescence (kit #32106; Pierce), followed by exposure to film. The signal from 
the gene of interest was normalized to the GAPDH signal using ImageJ software
RNAscope in situ hybridization
RNAscope in situ hybridization was performed as in (I). Briefly, RNAscope (Wang et al., 2012) 
probes detecting Gdnf (red) and Pvalb (green) mRNA were custom made by Advanced Cell 
Diagnostics and were hybridized to slices from cerebellum and striatum of 3 month old mice, 
according to manufacturer’s recommendations. 
Serum urea 
Serum urea levels were measured with standard kits (BioAssay Sytems).
Recombinant protein injections 
Pregnant dames were given a serial of intravenous injections of 10 µg recombinant fc-GFRa1 
fusion protein (R&D systems, catalog number 560-GR/CF) into tail vein from timed pregnancy 
E10.5 to E15.5. For controlling protein delivery to fetuses E13.5 pregnant NMRI dame was given a 
single 10 µg injection of fc-GFRa1 and was euthanized one hour later. 
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Double heterozygous GDNF hypermorphic and GFRa1 hypomorphic animals
GDNF hypermorphic and GFRa1 hypomorphic mouse models were generated by Dr Jaan-Olle 
Andressoo, as described in the publications I and II respectively. Healthy GdnfWT/hyper and Gfra1WT/
hypo animals were crossed with each other. Mice were maintained on a 129Ola/ICR/C57BL6 mixed 
genetic background, housed under a 12h/12h light/dark cycle at 20-22°C, with one mother and 
litter per cage. Standard chow and water were available ad libitum. All animal experiments were 
approved by the national Animal Experiment Board of Finland.
Immonohistochemistry
Immunohistochemisty of PGP9.5 was performed as described in publications II and III. The 
number of ganglia was quantified with ImagePro software. For tyrosine hydroxylase and PGP9.5 
immunohistochemistry sections were deparaffinized with xylene-alcohol-water series. Antigen 
retrieval was performed by boiling the samples 10 minutes in fresh 10 mM citrate buffer (pH 
6,0 + 0,05 % Tween 20) followed by cooling in the buffer. Quenching of endogenous peroxidase 
was carried out in 1:53 H2O2 in TBS solution for 30 min at RT. After washing with TBS-T (TBS 
with 0,1 % Tween 20) blocking was performed in 1,5 % normal goat serum in TBS-T for 30 min 
at RT. Incubation with primary antibody solution (Rabbit anti ubiquitin C-terminal hydrolase L1 
(PGP9.5) 1:250 BML PG9500, Enzo; mouse anti tyrosinehydroxylase, 1:000 MAB318, Millipore) 
was performed overnight at + 4 °C, incubation with secondary antibody solution (Biotinylated 
anti-rabbit 1:200  Vector kit; Donkey anti mouse Cy3 Jackson 715-165-150 1:400) was performed 
for 90 min at RT. After washing in TBS-T, fluorescent paraffin sections were mounted in Immu-
mount (Thermo-Scientific). Samples were imaged with Olympus BX-UCB microscope. As negative 
controls, either the primary or secondary antibodies were omitted.
Gastrointestinal transit time
P7.5 mice were fed a 100 µl bolus of 0.1 % medicinal carbon (Takeda) in 10 % sucrose solution. 
Mice were euthanized 30 minutes after dye dose and the small intestine transit time was measure 
as % distance traveled of the total small intestine length.
Experimental design and statistical analysis
All values are presented as mean ± SEM. Statistical significance level was set at p < 0.05. Statistical 
analysis was performed with GraphPad Prism 7.04 software. Appropriate statistical test was used 
for each dataset: one way ANOVA followed by Tukey’s HSD (honestly significant difference) or 
unpaired two-tailed t-test. Animal cohort sizes were selected by the three R principles. Genotypes 
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